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The opioid system consists of three receptors, mu, delta, and kappa, which are
activated by endogenous opioid peptides (enkephalins, endorphins, and dynorphins). The
endogenous cannabinoid system comprises lipid neuromodulators (endocannabinoids),
enzymes for their synthesis and their degradation and two well-characterized receptors,
cannabinoid receptors CB1 and CB2. These systems play a major role in the control of
pain as well as in mood regulation, reward processing and the development of addiction.
Both opioid and cannabinoid receptors are coupled to G proteins and are expressed
throughout the brain reinforcement circuitry. Extending classical pharmacology, research
using genetically modiﬁed mice has provided important progress in the identiﬁcation of the
speciﬁc contribution of each component of these endogenous systems in vivo on reward
process.This review will summarize available genetic tools and our present knowledge on
the consequences of gene knockout on reinforced behaviors in both systems, with a focus
on their potential interactions. A better understanding of opioid–cannabinoid interactions
may provide novel strategies for therapies in addicted individuals.
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INTRODUCTION
Drug abuse often leads to a complex pharmaco-dependent state
which is deﬁned by the term addiction. Addiction is consid-
ered as a neuropsychiatric disease. It develops from an initial
recreational drug use, evolves toward compulsive drug-seeking
behavior and excessive drug-intake with the appearance of nega-
tive emotional states such as anxiety or irritability when the drug
is not accessible, and uncontrolled intake reaching a stage where
the drug interferes with daily activities, despite the emergence
of adverse consequences (Leshner, 1997; Everitt and Robbins,
2005; Robinson and Berridge, 2008; Koob, 2009). This patholog-
ical process develops in 15–30% of casual drug users and several
factors may explain individual’s vulnerability to addiction, includ-
ing genetic, psychological and environmental factors (Swendsen
and Le Moal, 2011; Belin and Deroche-Gamonet, 2012; Pattij
and De Vries, 2013; Saunders and Robinson, 2013). Addiction
is a major threat to public health and represents a societal prob-
lem especially in developed countries and the economic cost it
entails (investments in research, treatment and prevention) is
considerable (Gustavsson et al., 2011).
Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, anandamide, N-arachidonoyl-
ethanolamide; CB1, type 1 cannabinoid receptor; CB2, type 2 cannabi-
noid receptor; cKO, conditional knockout mice; CPA, conditioned place
aversion; CP 55,940, (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-
4-(3-hydroxypropyl)cyclohexan-1-ol; CPP, conditioned place preference; CPu,
caudate putamen; DA, dopamine; DAGL, diacylglycerol lipase; FAAH,
fatty acid amide hydrolase; G protein, guanine nucleotide binding pro-
tein; GABA, c-aminobutyric acid; GPCR, G protein coupled receptor;
KO, knockout; MGL, monoacylglycerol lipase; NAPE-PLD, N-acyl phos-
phatidylethanolamine phospholipase D; THC, Delta-9-tetrahydrocannabinol;
WIN 55,212-2, 2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-
1,4-benzoxazin-yl-1-naphtalenylmethanone mesylate; WT, wild-type.
Among illicit drugs, opiate and cannabinoid derivatives are
highly abused in Europe. Morphine-like opiates are powerful
analgesics and currently represent the major therapeutic reme-
dies for the treatment of severe pain. They are also abused
for their recreational euphoric effects. In Europe, 1.3 million
people are addicted to heroin, the primary drug for which
treatment requests are sought. Cannabis is the most worldwide
consumed drug of abuse, with THC being the most abun-
dant active constituent found in the various preparations of
the drug. More than 73 million European citizens have used
cannabis in the last year and it is estimated that about 7% of
cannabis users has become dependent on this drug. There is also
a high prevalence of users who seek treatment for dependence on
it (http://www.emcdda.europa.eu/publications/edr/trends-develo
pments/2014). Interestingly, new derivatives of these abused drugs
are invading the market, notably through internet. Fentanyl
derivatives as new opioid drugs and synthetic cannabimimetics,
also known as “spices,” are becoming more and more popular
(Fattore and Fratta, 2011). These abusive substances interact with
two neuromodulator sytems, the opioid and the endocannabinoid
systems.
THE OPIOID SYSTEM
The opioid system consists of endogenous opioid peptides
(enkephalins, endorphins, and dynorphins) from precursors
(Penk, Pdyn, and Pomc) which activate three opioid receptors,
namely mu, delta, and kappa (Kieffer, 1995). The three mem-
brane receptors, cloned in the early nineties (Evans et al., 1992;
Kieffer et al., 1992; Simonin et al., 1994, 1995; Mestek et al., 1995)
are GPCR with coupling to Gi/Go proteins, of which the 3D
structure was recently resolved (see Filizola and Devi, 2014).
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Opioid receptors and endogenous opioid peptides are largely
expressed throughout the nervous system, noticeably within areas
of the neurocircuitry of addiction associated with reward, motiva-
tion, or learning and stress (Mansour et al., 1995; Le Merrer et al.,
2009; Koob and Volkow, 2010; Erbs et al., 2014). Besides its key
role in many aspects of addition (Lutz and Kieffer, 2013a), the
opioid system also plays a part in a diverse range of physiological
functions including nociception, mood control, eating behavior,
or cognitive processes (Contet et al., 2004; Pradhan et al., 2011;
Stein, 2013; Bodnar, 2014; Nogueiras et al., 2014).
THE ENDOCANNABINOID SYSTEM
The endocannabinoid system is a neuromodulatory system con-
sistingof twowell characterized transmembrane receptors coupled
to G protein (Gi/Go), CB1, and CB2 cloned in the 1990’s (Mat-
suda et al., 1990; Munro et al., 1993). The endogenous ligands
are lipid neuromodulators, the main ones being AEA and 2-AG.
Both are synthesized from phospholipid precursors and act locally
as retrograde regulators of synaptic transmission throughout the
central nervous system. These lipids are released by postsynaptic
neurons and mainly activate presynaptic cannabinoid receptors to
transiently or persistently suppress transmitter release from both
excitatory and inhibitory synapses (recently reviewed in Ohno-
Shosaku and Kano, 2014). Multiple pathways are involved in AEA
biosynthesis with several still not fully characterized enzymes.
AEA can be generated from the membrane phospholipid precur-
sorN-arachidonoyl phosphatidylethalonamine (NAPE) through a
two-step process with ﬁrst a calcium-dependent transacylase fol-
lowed by a phospholipase D (NAPE-PLD) hydrolysis (Liu et al.,
2008). Phospholipase C (PLC) and DAGL are involved in 2-AG
synthesis (Ahn et al., 2008). Their degradation is conducted by
two speciﬁc enzymatic systems, the FAAH (Cravatt et al., 1996)
and the MGL (Dinh et al., 2002), for AEA and 2-AG, respectively
(Ahn et al., 2008). The endocannabinoid system plays a key role in
energy balance, modulation of pain response, with processing of
central and peripheral pain signals, learning and memory, reward
and emotions. It has also been shown to be involved in neuroge-
nesis and would play a neuroprotective role in some pathological
conditions (for recent reviews see Gardner, 2005; Solinas et al.,
2008; Maldonado et al., 2011; Zanettini et al., 2011; Panagis et al.,
2014; Piomelli, 2014). Distribution of the two receptors in the
central and peripheral system is rather different (Pertwee, 2010).
Indeed, CB1 is highly abundant in the central nervous system in
areas involved in reward, regulation of appetite and nociception
(see Figure 1) while CB2 was initially described as a peripheral
receptor (Maldonado et al., 2006, 2011; Mackie, 2008). Recent
studies have proposed a low but signiﬁcant expression of this
receptor in several brain structures including striatum, hippocam-
pus, and thalamus (Wotherspoon et al., 2005; Gong et al., 2006;
Onaivi et al., 2006) and more recently into ventral tegmental area
neurons (Zhang et al., 2014). Only few data are therefore available
for the CB2 receptor in central function but growing evidence sug-
gest a role in addictive processes, with an implication in cocaine,
nicotine, or ethanol effects (Xi et al., 2011; Ignatowska-Jankowska
et al., 2013; Navarrete et al., 2013; Ortega-Alvaro et al., 2013). To
our knowledge, no data is available thus far concerning a potential
role of CB2 in opioid mediated responses. Interestingly, other
non-CB1 and non-CB2 receptors have been proposed to interact
with endocannabinoids like the orphanGPCRGPR55 or a channel
vanilloid TRPV1 recognizing capsaicin. These interactions could
potentially explain some pharmacology of cannabis that cannot
be accounted for by CB1 and CB2 activation, but further studies
using KO approaches may help to provide a better understanding
of this pharmacology (De Petrocellis and Di Marzo, 2010).
CROSS TALK BETWEEN THESE NEUROTRANSMITTER SYSTEMS
Many neurotransmitter systems are involved when addiction
develops, and both opioid and endocannabinoid systems are
FIGURE 1 | Schematic representation of the distribution of mu opioid
and CB1 cannabinoid receptors in the central nervous system. CB1
receptor distribution over the whole central nervous system is indicated by
circle shapes with low (white), moderate (gray) and high (dark gray)
expression. Major localization of CB1 receptor (mRNA and protein) is in
cortical areas, amygdala, striatum, and cerebellum. Moderate and low
expression levels are observed in thalamic, hypothalamic, and brainstem
regions. Interestingly, the mu opioid receptor is also expressed in these CB1
expressing brain areas but at various levels, indicated by diamonds for low
(one), moderate (two), and high (three) expression levels (adapted from
Mackie, 2005; Erbs et al., 2014 and references therein). Amb, ambiguous
nucleus; BLA, basolateral amygdala; CeA, central amygdala; CPu, caudate
putamen; DB, diagonal band; DRN, dorsal raphe nucleus; GP, globus pallidus;
Hyp, hypothalamus; LC, locus coeruleus; LHb, lateral habenular nucleus;
mHb, medial habenular nucleus; NAc, nucleus accumbens; OB, olfactory
bulb; PAG, periaqueductal gray; SNr, substantia nigra pars reticulate; Sol,
nucleus of the solitary tract; STh, subthalamic nucleus (ventral thalamus); Th,
dorsal thalamus; Tu, olfactory tubercle; VTA, ventral tegmental area.
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major players in addictive disorders. In addition to their spe-
ciﬁc ligands, both systems have also been implicated in the action
mechanism of several other addictive drugs, like ethanol, nico-
tine, or psychostimulants. Although the endocannabinoid system
has been known to interact with other systems like hypocre-
tin, dopaminergic, and adenosinergic systems (Fernandez-Ruiz
et al., 2010; Ferre et al., 2010; Tebano et al., 2012), its interac-
tion with the opioid system is now well established (Fattore
et al., 2005; Vigano et al., 2005; Robledo et al., 2008; Trigo et al.,
2010). These two systems share neuroanatomical, neurochemi-
cal, and pharmacological, characteristics, this phenomenon is yet
less well documented for the CB2 receptor. Figure 1 illustrates
brain structures expressing CB1 receptors and depicts expres-
sion level of mu opioid receptors in these areas. The existence
of a speciﬁc opioid–cannabinoid interaction in the modula-
tion of neurochemical effects as well as behavioral responses
associated with reward and relapse have been demonstrated
by pharmacological and genetic approaches but experimental
results remain controversial (Manzanares et al., 1999; Fattore et al.,
2005; Maldonado et al., 2011). Furthermore, molecular interac-
tions between receptors have been shown with colocalization or
heterodimerization data mainly for CB1 and delta or mu opioid
receptors within spinal cord, striatum, or locus coeruleus. This
phenomenon may also account for speciﬁc responses at the cel-
lular level (Scavone et al., 2013; Massotte, 2014). However, the
physiological effects of these molecular interactions have had yet
to be revealed.
AIM OF THE REVIEW
Pharmacological evidence for cross-talk with the synergetic effect
of opioid and cannabinoid ligands in many functions related to
addiction (mood, stress, learning process . . .) have been revealed
and here we will review the implications of both systems regard-
ing reward aspects. As several reviews have recently reported about
these interactions (see above), we will focus our interest only on
genetic studies using KO mice. We will ﬁrst present the available
genetic tools for both systems. We will then provide an update of
results on reinforced behaviors to highlight insights into the par-
ticular role of the opioid system in responses to cannabinoids and
the endocannabinoid system in responses to prototypical opiates
like morphine. We will summarize the behavioral responses of KO
mice to these drugs and propose a role for the potential interaction
of these two endogenous systems in addictive processes.
REWARD MEASURES IN MICE
Opioid and cannabinoid derivatives induce dependence. To study
rewarding effects mediated by speciﬁc brain circuits in preclin-
ical research, several behavioral models have been developed
in rodents. The most reliable model to evaluate the reinforc-
ing properties of a psychoactive compound in rodents is the
self-administration (SA) paradigm which is based on a volun-
tary procedure to obtain the drug, coupled with the association
of a signal (Panlilio and Goldberg, 2007). This operant sys-
tem allows measuring both rewarding as well as motivational
effects of an abused drug. Several aspect of addictive behav-
iors can be evaluated with this paradigm, with acquisition (ﬁxed
ratio) and motivation (progressive ratio) for the drug as well
as extinction (response rate when drug-delivery has stopped)
and reinstatement induced by cues, context or stress (relapse
to drug-seeking) which will reﬂect aspects of excessive con-
sumption (Sanchis-Segura and Spanagel, 2006). Intravenous SA
has been extensively developed for opiates but more difﬁcult
to establish for cannabinoid compounds. Adaptations includ-
ing drug priming, low doses, food restriction, animal restraint,
or use of various cannabinoid agonists were often necessary
(Maldonado, 2002; Panlilio et al., 2010; Panagis et al., 2014). Nev-
ertheless, iv SA of both THC and the synthetic cannabinoid
WIN55,212-2 have been successfully described both in rats and
mice, and extended to the study of KO mice (Martellotta et al.,
1998; Fattore et al., 2001; Mendizabal et al., 2006; Flores et al.,
2014). A very recent study demonstrated for the ﬁrst time that
2-AG is self-administered by rats and stimulates DA transmission
(De Luca et al., 2014).
In addition, a well-accepted model to study the reinforcement
properties of abused drugs is the CPP which is a non-operant
paradigm. The reinforcing properties are associated with environ-
mental stimuli (cues), such as the context in which the drug is
administered. If the drug or a combination of drugs is aversive,
animals avoid the drug-paired compartment (CPA) (Tzschentke,
2007). These paradigms have been widely used to study opiates
or cannabinoids effects in mutant mice. However, data reporting
reinforcing properties for THC and other cannabinoids are rather
controversial with a critical concern about experimental condi-
tions,with dose or injection schedule asmajor parameters to reveal
either positive CPP or negative CPA properties of cannabinoids
(Panagis et al., 2014).
On top of these two main paradigms (SA and CPP) other tasks
have been developed like intracranial self-stimulation (ICSS) as
a model to measure reward-facilitating effect of an abused sub-
stance although it is rather difﬁcult to set up in mice and therefore
little data is available (Panagis et al., 2014). Furthermore, with-
drawal signs appear after cessation of chronic drug exposure,
either spontaneously or precipitated by an antagonist treatment,
and these signs can be scored for providing an index of depen-
dence (Maldonado et al., 1996). In order to make a meaningful
comparison in the evaluation of the speciﬁc involvement of com-
ponents of opioid or cannabinoid systems in reward process, it
is crucial to compare, when possible, the different mutant lines
with their WT littermates in the exact same procedure to avoid
bias from technical or experimental variations. Interestingly, such
direct comparison has been recently performed for the four com-
ponents of the opioid system (mu, delta, Penk, and Pdyn) to
demonstrate differential behavior in the acquisition and relapse
of cocaine SA in the four mutant mice (Gutierrez-Cuesta et al.,
2014).
GENERATION OF DEFICIENT MICE IN REGARDS TO
COMPONENTS OF THE OPIOID OR CANNABINOID SYSTEMS
For each component of the opioid and the cannabinoid systems,
various lines of genetically modiﬁed mice have been generated.
Table 1 presents a list for conventional KO mouse lines that have
been described so far. The original papers describing the develop-
ment of the constitutive deletion are presented with the targeted
area of the suppressed gene.
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Table 1 | Knockout mouse lines for the opioid and the cannabinoid
systems.
Gene knockout Targeted exon Reference
Opioid system
Oprm Exon 2 Matthes et al. (1996)
Exon 1 Sora et al. (2001)
Exon 1 Tian et al. (1997)
Exons 2 and 3 Loh et al. (1998)
Exon 1 Schuller et al. (1999)
Exons 2 and 3 van Rijn andWhistler (2009)
Exon 11 (splice
variant)
Pan et al. (2009)
Oprd Exon 2 Zhu et al. (1999)
Exon 1 Filliol et al. (2000)
Exon 2 van Rijn andWhistler (2009)
Oprk Exon 1 Simonin et al. (1998)
Exon 3 Hough et al. (2000)
Exon 3 Ansonoff et al. (2006)
Exon 2 van Rijn andWhistler (2009)
Exon 3 Van’t Veer et al. (2013)
Oprm/oprd Simonin et al. (2001)
Oprm/oprd/oprk Simonin et al. (2001)
Clarke et al. (2002)
Penk Exon 3 Konig et al. (1996)
Exon 3 Ragnauth et al. (2001)
Pdyn Exon 3 Shariﬁ et al. (2001)
Exon 3 Zimmer et al. (2001)
Exon 3 Loacker et al. (2007)
Pomc Exon 3 Rubinstein et al. (1996)
Exon 3 Yaswen et al. (1999)
Penk/Pdyn Clarke et al. (2003)
Cannabinoid system
Cnr1 Exon 2 Zimmer et al. (1999)
Exon 2 Ledent et al. (1999)
Exon 2 Marsicano et al. (2002)
Exon 2 Robbe et al. (2002)
Cnr2 Exon 2 Jarai et al. (1999), Buckley
et al. (2000)
Exon 2 Wotherspoon et al. (2005)
FAAH Exon 1 Cravatt et al. (2001)
MGL Exon 3 Uchigashima et al. (2011)
Exons 3 and 4 Taschler et al. (2011)
Intron 3–exon 4
(gene trapping)
Schlosburg et al. (2010)
Exons 1 and 2 Chanda et al. (2010)
NAPE-PLD Exon 4 Leung et al. (2006)
Exon 3 Tsuboi et al. (2011)
(Continued)
Table 1 | Continued
Gene knockout Targeted exon Reference
DAGLalpha Exon 1 Gao et al. (2010)
Exons 3 and 4 Tanimura et al. (2010)
Intron 4-Exon 1(gene
trapping)
Yoshino et al. (2011)
DAGLbeta Exon 1 Gao et al. (2010)
Exons 10 and 11 Tanimura et al. (2010)
Exon 1 (gene
trapping)
Yoshino et al. (2011)
cnr1/cnr2 Jarai et al. (1999)
FAAH/cnr1 Sun et al. (2009)
FAAH/cnr2 Sun et al. (2009)
FAAH/cnr1 Wise et al. (2007)
This table summarizes the published report of KO mouse lines for the different
partners of these two systems and combinatorial lines, with the original papers
as reference. The area of the gene that has been targeted is indicated.
THE OPIOID SYSTEM
For components of the opioid system, the mu receptor drew the
most attentionwith the description of six distinct geneticallymod-
iﬁed lines targeting the coding regions of the oprm gene, with
either exon 1, exon 2 or both exons 2 and 3 targeted for the dele-
tion (Matthes et al., 1996; Tian et al., 1997; Loh et al., 1998; Schuller
et al., 1999; Sora et al., 2001; Pan et al., 2009; van Rijn andWhistler,
2009). Interestingly, the mu opioid receptor KO mice allowed to
unambiguously demonstrate that the mu receptor was the molec-
ular target for morphine, the prototype of opiate ligand widely
used in clinics for its therapeutic effect in pain relief. Morphine had
neither analgesic effects nor rewarding properties in these mutant
mice (for reviews, see Contet et al., 2004; Gaveriaux-Ruff, 2013).
An additional mutant line was constructed which targeted exon
11, a splice variant for the mu receptor, located upstream of exon
1. In these deﬁcient mice, a 25% decrease of receptor expression
was observed (Pan et al., 2009), leading to difﬁcult interpretation
of the KO effect on opiate pharmacology (Gaveriaux-Ruff, 2013).
For deletion of the delta receptor, either exon 1 or 2 were tar-
geted in the oprd gene (Zhu et al., 1999; Filliol et al., 2000; van Rijn
and Whistler, 2009). These mice were characterized for behavioral
responses related to mood and analgesia, but the contribution of
delta receptor in reward processes was less clear (Pradhan et al.,
2011; Charbogne et al., 2014). Five distinct constructions have
been reported targeting either exon 1, 2, or 3 of the oprk gene to
obtainKOmice for the kappaopioid receptor (Simonin et al., 1998;
Hough et al., 2000; Ansonoff et al., 2006; van Rijn and Whistler,
2009; Van’t Veer et al., 2013). The two most recent mutants were
strategically obtained in order to generate a parallel conditional
KO mice (see below) using a Cre-lox approach, with targeted
exons ﬂoxed with loxP sites. The mutation impaired pharma-
cological actions of the selective kappa-agonist U-50,488H, and
revealed a tonic implication of kappa receptors in the perception
of visceral pain. Morphine-CPP was unchanged, but both mor-
phine withdrawal signs as well as emotional responses during
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opiate abstinence were reduced (Simonin et al., 1998; Lutz et al.,
2014), suggesting an anti-reward role for kappa receptors.
Mice with deleted opioid peptide precursors were also gener-
ated. For proopiomelanocortin (Pomc), two lines were produced,
one speciﬁcally deleting βendorphin (Rubinstein et al., 1996)while
the second was targeting the whole coding region, deleting both
opioid and non-opioid active petides (Yaswen et al., 1999). KO
mice for Penk gene were generated by two distinct laboratories,
both leading to deletion of the 5′ part of exon 3 (Konig et al., 1996;
Ragnauth et al., 2001). For deleting dynorphin in mutant animals,
exons 3 and 4 (Shariﬁ et al., 2001) or exon 3 with a part of exon 4
(Zimmer et al., 2001) of the Pdyn gene were targeted. Data from
peptide KO mice in regards to opiate rewarding effect were more
complex. The βendorphin KO mice showed increased (Skoubis
et al., 2005) or unchanged (Niikura et al., 2008) morphine-CPP
depending on the dose and paradigm used and it was invariable
both in mice lacking Penk (Skoubis et al., 2005) or Pdyn (Zimmer
et al., 2001; Mizoguchi et al., 2010).
THE CANNABINOID SYSTEM
Four independent KO lines have been generated for the CB1 recep-
tor, encoded by a single large coding exon in the cnr1 gene (exon 2).
The ﬁrst three lines were generated with the introduction of a PGK
or neomycine resistance cassette in the coding region (Ledent et al.,
1999; Zimmer et al., 1999; Robbe et al., 2002). For the fourth line,
loxP sites were introduced ﬂanking exon 2 and this ﬂoxed line was
further crossedwith a line constitutively expressing theCre recom-
binase enzyme, therefore generating a full CB1 KO by deletion of
the sequence between the two lox P sites (Marsicano et al., 2002).
These mice were mostly unresponsive to cannabinoid ligands in
mediating analgesia, reinforcement, hypothermia, hypolocomo-
tion, and hypotension (Valverde and Torrens, 2012; Nadal et al.,
2013). Two mouse lines were described for the deletion of the cnr2
gene coding for CB2 receptor, one by Zimmer’s team (Jarai et al.,
1999; Buckley et al., 2000) and the other one by the company Delt-
agen (Wotherspoon et al., 2005). Both were developed by deleting
part of the coding region (in exon 2), leaving the start codon
with a portion of the amino terminus sequence and aminoacids
coding for some transmembrane domains of the receptor. In
these constructions expression of the amino-terminal part of the
CB2 receptor could potentially occur, but in both cases, it was
shown that the receptor was non-functional in the mutant mice
(Dhopeshwarkar and Mackie, 2014). Two mutant lines have been
described for the NAPE-PLD enzyme involved in AEA synthesis,
targeting exon 3 (Tsuboi et al., 2011) or exon 4 (Leung et al., 2006).
These KO mice have highlighted the complexity of AEA synthe-
sis with both calcium-dependent and -independent mechanisms.
Two isoforms of DAGLα and DAGLβ responsible for the synthesis
of 2-AG have been described and KO lines have been generated for
each of themwith bothhomologous recombination and gene trap-
ping approaches (Gao et al., 2010; Tanimura et al., 2010; Yoshino
et al., 2011). The DAGLα KO animals showed a markedly reduced
2-AG brain content whereas levels were normal in brain regions
of KO for the β isoform indicating a much greater contribution
of DAGLα to 2-AG biosynthesis in the central nervous system.
These mutant mice were particularly useful in the characterization
of DAGL involvement in retrograde endocannabinoid signaling
(Frazier, 2011). The endocannabinoid system is characterized by
a rapid catabolism of the endogenous ligands. Among the degrad-
ing enzymes of endocannabinoids, FAAH is the major enzyme
responsible for the degradation of AEA and one KO line was gen-
erated targeting exon 1 of the Faah gene (Cravatt et al., 2001).
Thesemutantmice exhibitedmore than 15-fold higher brain levels
of AEA than WT animals and displayed reduced pain sensitivity.
The major degrading enzyme of the endocannabinoid 2-AG is
MGL and four KO lines were generated. Three KO lines target-
ing mgll gene exons 1 and 2 (Chanda et al., 2010), exon 3, or
exons 3 and 4 were recently generated with a Cre/lox approach
(Taschler et al., 2011; Uchigashima et al., 2011). Another line was
obtained by gene trapping technology (Texas Institute of Genomic
Medicine) with a gene trap cassette inserted into the mgll intron 3,
upstream of the catalytic exon 4 (Schlosburg et al., 2010). Genetic
deletion of MGL leads to alteration in endocannabinoid signal-
ing with increased brain 2-AG levels by ∼10-fold. These animals
were mainly characterized by behavioral consequences of the gene
deletion for pain perception (Schlosburg et al., 2010; Uchigashima
et al., 2011; Petrenko et al., 2014).
COMBINATORIAL MOUSE LINES
Interbreeding of mutant mouse lines allowed generating combi-
natorial mutant mice both within the opioid and the cannabinoid
systems (see references in Table 1). These combinatorial lines
constituted useful tools to clarify the speciﬁc role of particular
components of both systems in reward and analgesia, as well as
to evaluate in vivo selectivity for speciﬁc ligands and receptor
subtype identiﬁcation (Kieffer and Gaveriaux-Ruff, 2002; Nadal
et al., 2013). Data for reward responses obtained using multi-
ple mutants for cannabinoid or opioid components are detailed
below.
COMPENSATORY EFFECTS OF THE NULL MUTATION
Globally, a normal development was described for the various
mutant lines, with KO mice being fertile, caring for their off-
spring, and not showing any major behavioral abnormalities. A
higher mortality rate was described for one of the CB1 KO line
(Zimmer et al., 1999) but not reported for the two others. Inter-
estingly, among the combinatorial mice, the triple mutant of the
opioid receptors present a striking increase in body weight and
size, but this obese-like phenotype needs further characterization
(Befort and Gaveriaux-Ruff, personal communication). Compen-
satory mechanisms may have developed in some KO animals, but
no systematic studies are available. Deletion of opioid receptors
did not markedly modify the expression or activity of the other
opioid receptors or the expression of opioid peptides as described
by the initial characterizations of the distinct mutants lines (see
references in Table 1 and Kitchen et al., 1997; Slowe et al., 1999;
Oakley et al., 2003). A complete autoradiographic mapping of the
delta KO mice indicated decreased binding levels of mu and kappa
ligands in speciﬁc brain areas (Goody et al., 2002). Deletion of opi-
oid peptides modiﬁed other partners of the opioid system, with a
region-dependent increased of both mu and delta receptor expres-
sion levels observed in the Penk KO line (Brady et al., 1999; Clarke
et al., 2003) and for the three opioid receptors in the Pdyn and
the double Pdyn/Penk mutant line with no additive effects (Clarke
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et al., 2003). Interestingly, speciﬁc changes of CB1 receptor expres-
sion or activity were reported in mu and delta opioid receptor
mutant lines (Berrendero et al., 2003). In the mu KO brain, there
was no difference in CB1 expression but a decreased efﬁcacy of
the classical cannabinoid agonist WIN 55,212-2 was observed
speciﬁcally in the CPu while both density of CB1 receptor and
activation by WIN 55,212-2 increased in substantia nigra of delta
KO animals.
Compensatory effects in KO animals concerning the cannabi-
noid system have been described both for receptor or catabolic
enzyme KO mice. The invalidation of the CB1 receptor gene was
associated with age-dependent adaptive changes of endocannabi-
noid metabolism, with increased FAAH and AEA membrane
transporter activities in KO hippocampus and cortex, decreased
AEA content in hippocampus but no change in 2-AG levels (Di
Marzo et al., 2000; Maccarrone et al., 2001, 2002). In the FAAH
KO mice, CB1 receptor mRNA decreased in CPu, nucleus accum-
bens (core), hippocampus (CA1), hypothalamic nucleus (VMN),
and amygdala. Its functional activity was also markedly reduced
in CPu, the core of nucleus accumbens, and CA3 region of the
hippocampus (Vinod et al., 2008). Interestingly, reduction of CB1
receptor density and activitywere also observed inMGLKOmouse
brain, which may prevent the manifestation of the dramatically
enhanced 2-AG behavioral effects in these mice (Chanda et al.,
2010; Schlosburg et al., 2010). In DAGLα- and DAGLβ-KO, no
difference was reported for CB1 mRNA (Gao et al., 2010) or pro-
tein (Tanimura et al., 2010) levels in comparison to WT mice.
In these KO mice, CB1 brain functional signaling was unaltered
(Aaltonen et al., 2014). To our knowledge, no data is available
for any compensatory effect on CB2 expression or activity in the
distinct cannabinoid KOs. However, some reports indicate modi-
ﬁcations of the opioid system in CB1 KO animals. An increase of
both enkephalin and dynorphin mRNA expression was observed
in the striatum (Steiner et al., 1999; Gerald et al., 2006, 2008) as
well as an increase in kappa and delta opioid receptor activities
without changes in their binding (Uriguen et al., 2005). No com-
pensatory changes of mRNA levels for the three opioid receptors
were reported in dorsal root ganglia or spinal cord of the CB1
KO animals (Pol et al., 2006). In FAAH KO mice, Penk mRNA
expression was decreased in both CPu and nucleus accumbens
which paralleled a reduced mu opioid receptor functional activity
(Vinod et al., 2008). Noteworthy, these compensatory alterations
of opioid or cannabinoid components in speciﬁc regions of the
mutant lines could account for interactions of the two systems
which may be relevant for neuroadaptative processes involved in
drug dependence.
CONDITIONAL APPROACHES
Knockout mice are very useful tools for understanding the
contribution of each component of these systems in vari-
ous conditions including pain, mood disorders or addiction
(Valverde and Torrens, 2012; Gaveriaux-Ruff, 2013; Lutz and Kief-
fer, 2013b; Nadal et al., 2013; Charbogne et al., 2014). Recent
approaches using gene manipulation in mice have been developed
with the widely used Cre-loxP recombinase system to generate
cKO (Fowler and Kenny, 2012; Table 2). It consists of crossing
mice whose target genes are ﬂoxed (ﬂanked with two loxP sites)
together with mice expressing the Cre-recombinase under a spe-
ciﬁc promoter. This allows a time-, organ- or site-speciﬁc deletion
of a target gene. This strategy allowed uncoupling the central and
peripheral functions of CB1 receptors (Agarwal et al., 2007) and
more recently of mu or delta opioid receptors (Gaveriaux-Ruff
et al., 2011; Weibel et al., 2013) using the promoter of the channel
Nav1.8 only expressed inDRGs, revealing a key role for these recep-
tors expressed in primary nociceptive neurons in inﬂammatory
pain. To investigate molecular mechanisms at the level of neuronal
circuitry, selective deletionof a particular gene can also be achieved
in speciﬁc neuronal types. For example, deletion of the delta opi-
oid receptors speciﬁcally in forebrain GABAergic neurons was
obtained by crossing a delta opioid ﬂoxed mouse line (Gaveriaux-
Ruff et al., 2011) togetherwith a dlx5-6-Cremouse line, speciﬁcally
expressing the Cre-recombinase in GABAergic forebrain neurons
in order to investigate the role of these speciﬁc delta receptors in
anxiety (Chu Sin Chung et al., 2014). This latter mouse line was
previously crossed with the CB1 ﬂoxed mice to successfully obtain
a GABA-CB1 conditional mutant (Monory et al., 2006). These
mutants were also compared with several other cKO bearing a
deletion of CB1 receptor in differing speciﬁc neuronal popula-
tions: forebrain glutamatergic neurons (CB1CamKIIa-Cre mice
or CaMK-CB1KO), cortical glutamatergic neurons (CB1NEX-Cre
mice orGlu-CB1KO),both glutamatergic andGABAergic neurons
(Glu/GABA-CB1KO) or D1-dopaminergic neurons (CB1Drd1a-
Cre mice) (Marsicano et al., 2003; Monory et al., 2006, 2007;
Bellocchio et al., 2010) for studying the role of CB1 receptors as
well as behavioral and autonomic effects of the agonist THC.
For the opioid system, a recent study reported the generation
of a conditional mutant for the kappa opioid receptor, selec-
tively deleted in DA-expressing neurons. These kappa cKO mice
showed reduced anxiety-like behavior as well as increased sen-
sitivity to cocaine, consistent with a role for kappa receptors in
negative regulation of DA function (Van’t Veer et al., 2013). For
the cannabinoid system, cKO lines were also generated for the
CB1 receptor to study its speciﬁc implication in neurons (Maresz
et al., 2007) or peripheral nerves (Pryce et al., 2014), in serotonin-
ergic (Dubreucq et al., 2012b) or paraventricular (Dubreucq et al.,
2012a) and ventromedial (Bellocchio et al., 2013) hypothalamic
neurons. CB1 was also speciﬁcally deleted in astroglial cells to
investigate its role in working memory and long-term hippocam-
pal depression (Han et al., 2012). CB1 was deleted in speciﬁc cell
types like hepatocytes to study its role in ethanol-induced fatty
liver (Jeong et al., 2008), lymphocytes (Maresz et al., 2007) or epi-
dermal keratinocytes (Gaffal et al., 2013) to investigate its potential
role in regulation of inﬂammatory responses. Another strategy to
generate a cKO mouse is by using viral mediated construct car-
rying the Cre-recombinase injected directly in the structure of
interest of a target gene-ﬂoxed mouse. For example, the mu opi-
oid receptor was selectively deleted in the dorsal raphe, the main
serotoninergic brain area, and this deletion abolished the develop-
ment of social withdrawal in a model of heroin abstinence (Lutz
et al., 2014).
In opposition to the loss of function approach, recent stud-
ies used a rescue strategy where the target gene is re-expressed
in a null mutant, in only a subset of cells (Table 2). This
helps to provide information concerning the sufﬁcient role of
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Table 2 | Conditional knockout mouse lines for the opioid and the cannabinoid systems.
Target Gene Targeted neurons or structures for selective
deletion “loss of function”
Targeted neurons or structures for
selective expression “rescue”
Reference
Opioid system
Oprm Primary sensory neurons expressing Nav1.8 channel
(Nav1.8-Cre)
Weibel et al. (2013)
Subpopulation of striatal medium spiny
neurons
Cui et al. (2014)
Oprd Primary sensory neurons expressing Nav1.8 channel
(Nav1.8-Cre)
Gaveriaux-Ruff et al. (2011)
Forebrain GABAergic neurons (Dlx5/6-Cre) Chu Sin Chung et al. (2014)
Oprk Dopamine containing neurons (DAT-Cre) Van’t Veer et al. (2013)
Cannabinoid system
Cnr1 Principal forebrain neurons (CamKII-Cre) Marsicano et al. (2003)
Forebrain GABAergic neurons (Dlx5/6-Cre) Monory et al. (2006)
Cortical glutamatergic neurons (NEX-Cre) Monory et al. (2006)
Glutamatergic and GABAergic neurons (Glu/GABA) Bellocchio et al. (2010)
Primary sensory neurons expressing Nav1.8 channel
(Nav1.8-Cre)
Agarwal et al. (2007)
D1-dopaminergic neurons (Drd1a-Cre) Monory et al. (2007)
Serotoninergic neurons (TPH2-CreERT2) Dubreucq et al. (2012b)
Paraventricular hypothalamic neurons (Sim1-Cre) Dubreucq et al. (2012a)
Ventromedial hypothalamic neurons (SF1-cre) Bellocchio et al. (2013)
Neurons Nestin (Nes-Cre) Maresz et al. (2007)
Peripheral nerve (peripherin-Cre) Pryce et al. (2014)
Astrocytes (GFAP- CreERT2) Han et al. (2012)
Hepatocytes (Alb-Cre) Jeong et al. (2008)
Lymphocytes (lck-Cre) Maresz et al. (2007)
Keratinocytes (K14-Cre) Gaffal et al. (2013)
Dorsal telencephalic glutamatergic neurons
(Glu-CB1-RS)
Ruehle et al. (2013)
FAAH Nervous system (FAAH-NS) Cravatt et al. (2004)
This table summarizes the recent published reports of cKO mouse lines for the different partners of opioid and cannabinoid systems using “loss of function” or
“rescue” strategies.
the cell type expressing the target gene for a given function or
establishing whether other cellular subtypes or circuits are nec-
essary. When mu opioid receptor were re-expressed only in a
subpopulation of striatal direct-pathway neurons, in a mu KO
background, it restored opiate reward and opiate-induced stri-
atal DA release, partially restored motivation to self-administer
an opiate, but the rescued mice lacked opiate analgesia or with-
drawal (Cui et al., 2014). In a similar genetic strategy, CB1 receptor
expression was restored exclusively in dorsal telencephalic glu-
tamatergic neurons and proved sufﬁcient to control neuronal
functions that are in large part hippocampus-dependent, while
it was insufﬁcient for proper amygdala functions (Ruehle et al.,
2013). A conditional line where the expression of the FAAH
enzyme has been restricted to the nervous system (FAAH-NS) was
generated by crossing the FAAH KO line with a transgenic mouse,
expressing FAAH under the neural speciﬁc enolase promoter
(Cravatt et al., 2004). These mice exhibited a discrete subset of
the biochemical and behavioral phenotypes observed in FAAH
KO mice providing key insights into the distinct functions played
by the central and peripheral lipids transmitter signaling systems
in vivo.
In conclusion, despite potential limits such as developmental
effects of the mutation or compensatory mechanisms to over-
come consequences of the mutation, the use of mutants wherein
a component of either opioid or cannabinoid system is selectively
deleted from restricted neuronal populations provides essential
tools for a comprehensive understanding of mechanisms under-
lying cannabinoid or opioid effects in reward circuitry. So far,
these conditional lines for opioid and cannabinoid systems were
mostly characterized for pain or emotional behavioral responses,
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and few data is yet to become available for reward aspects
(Table 2).
CANNABINOID REINFORCING EFFECTS IN OPIOID
KNOCKOUT MICE
For evaluating the effect of cannabinoids in opioid mutant mice,
THC-induced CPP was mostly used (Table 3). Interestingly, the
same protocol was used for all tested opioid KO mice with 1 mg/kg
ip dose with a priming injection in the home cage. In these
conditions, no differences in place preference induced by THCwas
observed in delta or kappaKOmicewhile THC-CPPwas abolished
in mu KO mutants (Ghozland et al., 2002) as well as in the dou-
ble mu-delta KO mice (Castane et al., 2003). These data support
the hypothesis that mu receptors mediate rewarding properties of
THC. A similar protocol was used to induce aversion, but with a
higher dose of THC (5 mg/kg ip) wherein mu KO mice showed
a decreased CPA (Ghozland et al., 2002). THC-induced CPA was
abolished in similar conditions in both Pdyn (Zimmer et al., 2001)
and kappa KO mice (Ghozland et al., 2002). Self-administration
of the synthetic cannabinoid agonist WIN55,212-2 was success-
fully established in freely moving mice with a low priming dose
(0.1 mg/kg i.p.,) and with this protocol, Pdyn KO mice showed
facilitated SA (Mendizabal et al., 2006). Altogether, these data
support the idea that the kappa/dynorphin system plays a key
role in mediating cannabinoid dysphoric effects and therefore
negatively modulates their rewarding effects (Mendizabal et al.,
2006). Contribution of delta receptors in reward appears complex
(Charbogne et al., 2014; Gutierrez-Cuesta et al., 2014) and it has
Table 3 | Rewarding and dependence responses for cannabinoids and opioids measured in KO mouse lines for both systems.
Gene knockout Behavioral response Genotype effect Reference
Opioid system
Oprm CPP, THC (1 mg/kg, i.p.) Abolished Ghozland et al. (2002)
CPATHC (5 mg/kg, i.p.) Decreased
WD,THC (20 mg/kg, i.p. 2x/d, 6d) Unchanged
WD,THC (10 mg/kg, s.c. 5d) Unchanged Lichtman et al. (2001)
WD, THC (30 or 100 mg/kg, s.c. 5d) Decreased
Oprd CPP, THC (1 mg/kg, i.p.) Unchanged Ghozland et al. (2002)
CPATHC (5 mg/kg, i.p.) Unchanged
WD,THC (20 mg/kg, i.p. 2x/d, 6d) Unchanged
Oprm/Oprd CPP, THC (1 mg/kg, i.p.) Decreased Castane et al. (2003)
WD, THC (20 mg/kg, i.p. 2x/d, 6d) Decreased
Oprk CPP, THC (1 mg/kg, i.p.) Unchanged Ghozland et al. (2002)
CPP, THC (1 mg/kg, i.p.)w/o priming Present, absent inWT
CPA, THC (5 mg/kg, i.p.) Abolished
WD,THC (20 mg/kg, i.p. 2x/d, 6d) Unchanged
Penk WD,THC (20 mg/kg, i.p. 2x/d, 6d) Decreased Valverde et al. (2000)
Pdyn CPA, THC (5 mg/kg, i.p.) Abolished Ghozland et al. (2002)
SA,WIN 55,212(6.25 mg/kg/inf, i.v.) Increased Mendizabal et al. (2006)
SA,WIN 55,212(12.5 mg/kg/inf, i.v.) Abolished
WD,THC (20 mg/kg, i.p. 2x/d, 6d) Decreased Zimmer et al. (2001)
Cannabinoid system
Cnr1 CPP, morphine (5 mg/kg, s.c.) Abolished Martin et al. (2000)
CPA, morphine + naloxone (20–100 mg/kg i.p. over 6d + 0.1 mg/kg s.c.) Unchanged
CPP, morphine (4–8 mg/kg, i.p.) Unchanged Rice et al. (2002)
CPA, morphine + naloxone (8 mg/kg + 5 mg/kg, i.p.) Unchanged
SA, morphine (2 ug/kg.inf, i.v.) Abolished Cossu et al. (2001)
SA, morphine (1, 2, 4 ug/kg/inf, i.v.) Decreased Ledent et al. (1999)
WD, morphine (20 mg/kg to 100 mg/kg, 5d) Decreased
WD, morphine (75 mg/kg pellet, 5d) Decreased Lichtman et al. (2001)
CPA, U50,488H (1 mg/kg, s.c.) Abolished Ledent et al. (1999)
This table summarizes published reports of behavioral responses in reward and precipitated withdrawal for cannabinoids in opioid KO lines and opioids in cannabinoid
KO mutants (CPA, conditioned place aversion; CPP, conditioned place preference; d, day; inf, infusion; i.p., intraperitoneal; s.c., subcutaneous; WD, withdrawal; w/o,
without).
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not yet been established for cannabinoid reward, neither phar-
macologically nor genetically. A potential role of this particular
receptor in cannabinoid reward awaits further studies investigating
either cannabinoid SA (motivation aspects) or delta cKO mutant
responses (deletion of speciﬁc subpopulation of receptors).
Another aspect that was explored in opioid KO mice
is cannabinoid dependence. Upon chronic THC treatment,
antagonist-induced withdrawal signs measured in WT animals
were unchanged for Pdyn KO (Zimmer et al., 2001) or single
mutant mice for mu, delta or kappa opioid receptors (Ghoz-
land et al., 2002). Signs were attenuated in KO animals for Penk
(Valverde et al., 2000), for the double mu-delta receptor mutant
(Castane et al., 2003) as well as for mu receptor KO, at a high dose
(Lichtman et al., 2001) (Table 3). No data are yet available for the
other opioid peptide KO mice concerning cannabinoid physical
dependence. Collectively, available data indicate the involvement
of the enkephalinergic system, with a cooperative action of mu
and delta receptors, in the expression of cannabinoid dependence.
OPIOID REINFORCING EFFECTS IN CANNABINOID
KNOCKOUT MICE
Knockout approaches have greatly improved our knowledge on
the role of CB1 receptors in addiction in general, even though
contradictory data exist (Maldonado et al., 2006). In particular,
for opiate responses (Table 3) induced by mu agonists, CB1 KO
mice showed no morphine-induced place preference (5 mg/kg,
s.c., 3 injections over 6 days) (Martin et al., 2000) and a dimin-
ished propensity to self-administer morphine (Ledent et al., 1999;
Cossu et al., 2001). A microdialysis study revealed that morphine-
induced increase of extracellular DA was not observed in CB1
KO mice (Mascia et al., 1999). Taken together, these data suggest
a reduction in morphine’s reinforcing activity in the absence of
the CB1 receptor. Another study could not reveal any changes
in place preference using a slightly more intensive conditioning
paradigm and a different set up with two doses of morphine (4
or 8 mg/kg, four injections over 4 days) (Rice et al., 2002). Inter-
estingly, no differences between WT and CB1 KO mice could be
observed in aCPAparadigmwhere the opioid antagonist naloxone
was used to induce withdrawal in morphine-treated mice via two
distinct paradigms (Martin et al., 2000; Rice et al., 2002). Upon
chronic morphine treatment, naloxone-induced withdrawal signs
measured in WT animals were attenuated (Ledent et al., 1999;
Lichtman et al., 2001). Together, these ﬁndings suggest that CB1
receptors are not involved in the disphoric effects of morphine
withdrawal (CPA) but are noticeably required for the development
of physical dependence or of somatic signs of opiate withdrawal.
Surprisingly, other important effects of morphine, like acute
induced analgesia and tolerance to chronic morphine-induced
analgesia, were not altered in CB1 KO animals. These ﬁndings
together with the data on mu opioid KO mice with cannabinoid
treatments suggest a bidirectional inﬂuence of mu opioid and CB1
cannabinoid receptors on reward processes. Aversive effects of the
kappa opioid agonist U50,488H were also blunted in CB1 recep-
tor KO mice (Ledent et al., 1999). Together with the data of kappa
opioid and Pdyn KO mice, it indicates that both cannabinoid and
opioid systems modulate negative motivational drug effects. To
our knowledge, no data concerning the speciﬁc effect of delta
selective opioid agonists on reward in CB1 KO mice are avail-
able. Interestingly, it has been demonstrated that the absence of
CB1 receptor also results in a reduction of the sensitivity to the
rewarding properties of sucrose (Sanchis-Segura et al., 2004), as
well as other reinforcers (for recent reviews, see (Lopez-Moreno
et al., 2010; Maldonado et al., 2013). Together with pharmacologi-
cal approaches (Maldonado et al., 2006),KOdata therefore provide
conﬁrmatory support that CB1 receptor play a modulatory role in
the reinforced behaviors maintained by sucrose and some other
reinforcers with, in particular, a mutual interaction of opioid and
cannabinoid systems.
For the other components of the endocannabinoid system,
no speciﬁc data for genetically modiﬁed animals were reported
for the investigation of opioid reward, although pharmacological
inhibition of the endocannabinoid catabolic enzymes attenuates
both naloxone-induced withdrawal as well as spontaneous with-
drawal signs in morphine dependent mice (Ramesh et al., 2011,
2013), indicating a potential role of these enzymes in opioid
dependence.
CONCLUSION AND PERSPECTIVES
Globally, despite some compensatory alterations at both opioid
and cannabinoid levels in mutant lines, KO studies have provided
insights into the mutual role of both opioid and cannabinoid
systems on reward. In particular, these studies have highlighted
the major role for both mu opioid and CB1 receptors in these
processes. Clearly, the mu opioid receptor is a convergent molec-
ular target mediating rewarding properties of opioid compounds
but also of other drugs of abuse, including cannabinoids. CB1
receptor also appears as a modulator of opioid reward. On the
other hand, KO approaches for endogenous opioid peptides or
enzymes for synthesis or degradation of endocannabinoids have
been very useful to clarify their speciﬁc role in both endoge-
nous systems but less/no data are available for reward mecha-
nisms. These mutants therefore need further investigations to
clarify their potential implication in cannabinoid/opioid reward
aspects.
Conventional genetically modiﬁed animals have strengthened
our current knowledge of the interaction between these two sys-
tems, but further studies using conditional approaches will be
necessary to clarify the potential crosstalk existing speciﬁcally in
reward processes. Interaction between these two neuromodula-
tor systems may be dependent on the brain area where it occurs,
even inside the brain rewarding networks (Parolaro et al., 2010).
Both mu opioid and CB1 receptors are highly expressed in these
networks in similar brain structures and a potential interaction in
areas where they are both strongly expressed is probable. Notice-
ably, opposite expression levels are observed in discrete areas
like amygdala (BLA versus central amygdala) as well as habe-
nula (medial versus lateral nuclei) and these differences may also
account for a modulatory role of the two systems in reward pro-
cesses (Figure 1). Approaches using double mutants for both
receptors would be useful to further understand their mutual
role in drug reward. Moreover, in this perspective, conditional
approaches will surely provide invaluable insights into opioid and
cannabinoid interaction at the circuitry level. The growing num-
ber of cKO mutant lines becoming available will help this side of
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research. Likewise, the implication of the CB2 receptor in these
interactions has not yet been explored and may be particularly
relevant in speciﬁc brain structures. In fact, demonstration of
CB2 expression in several brain structures has opened a ﬁeld of
investigation for a possible role in addiction that should help to
reveal potential direct interaction between CB2 and the opioid
system.
G protein coupled receptor can associate as heteromers and
extended research is now directed toward elucidating the phys-
iological role of such heteromers and ﬁnding therapeutical
approaches targeting these entities (see recent reviews Fujita et al.,
2014; Massotte, 2014). Several lines of evidence have suggested
interactions between delta or mu opioid receptors and the CB1
receptors. Close vicinity of CB1 receptors with mu or delta
opioid receptors has recently been established at the neuronal
level, suggesting heteromeric formation in vivo and potential
impact on both receptors signaling properties. A recent study
demonstrated an important role for the heterodimer CB1-delta
in neuropathic pain where cortical functions of delta receptor
were altered (Bushlin et al., 2012). CB1 and mu receptors asso-
ciate as heteromers in cultured cells and a recent study showed that
bivalent ligands for both receptors are potent analgesic devoid of
tolerance (Le Naour et al., 2013), suggesting potential functional
heteromers in pain. Therefore, one can easily predict that similar
mechanisms may occur in another pathological state like addic-
tion and this opens up new prospects for pharmacological action
of cannabinoid and opioid drugs. In this context, it will be critical
to see whether CB2 also plays a role as a potential heteromeric
interactor with opioid receptors.
No effective therapeutic approaches for cannabis dependence
are currently available and opioid addiction therapies are not fully
satisfying for all patients. Further studies are therefore needed
to clarify the mechanistic basis of interaction of the two sys-
tems, which would aid in the development of drug therapies
to reduce dependence and abuse. Antibodies or bivalent lig-
ands as mentioned previously represent interesting therapeutic
targets. In addition, dual enkephalinase inhibitors and cannabi-
noid catabolic enzyme inhibitors have been proposed as attractive
therapeutic targets to treat pain (Roques et al., 2012) and such bi-
functional compoundsmay also be relevant as promising strategies
for alleviating dependence.
Substantial progress has been made in understanding the cel-
lular and molecular mechanisms of prolonged use of cannabinoid
or opioid drugs (Kreek et al., 2012; Fratta and Fattore, 2013).
In addition to their direct role in reward, interaction between
opioid and cannabinoid neuromodulator systems has been pro-
posed to explain some aspects of vulnerability to addiction and,
in this perspective, recent attention has been focused on yet
another critical level, epigenetics. These molecular processes,
including methylation of DNA, post-translational modiﬁcations
of histones and regulation by microRNA, regulate gene expres-
sion and are crucial in long-term adaptations induced by drugs
(Nestler, 2014). Recent studies have shown a direct associa-
tion between THC-induced Penk upregulation through reduction
of histone H3 lysine 9 pattern of methylation and increased
heroin SA (Tomasiewicz et al., 2012). Adolescent THC-exposure
also resulted in altered heroin SA in the subsequent generation
of rats, an effect associated with changes in mRNA expression
of cannabinoid, DA, and glutamatergic receptor genes in the
striatum, suggesting adaptations to long-term drug effect and
germline transmission, most likely involving epigenetic changes
(Szutorisz et al., 2014). How these neuromodulator systems are
dependent on various internal and external environmental fac-
tors, and therefore are involved in epigenetics and whether one
system inﬂuences the epigenetic machinery to control the other
system, are unresolved questions for upcoming studies (D’Addario
et al., 2013). Future investigation in this ﬁeld will be necessary to
better delineate the neurobiological mechanisms underlying these
neuroadaptations.
ACKNOWLEDGMENTS
I would like to thank Dr. D. Massotte for constant support and
fruitful discussions and M. Sturgis for English proof reading of the
manuscript. I would like to thank funding sources including the
Centre National de la Recherche Scientiﬁque and the Université de
Strasbourg. I would like to dedicate this review to my dear former
colleague and friend Hans Matthes, who constructed the ﬁrst mu
opioid knockout mouse, and who passed away unexpectedly this
summer.
REFERENCES
Aaltonen, N., Riera Ribas, C., Lehtonen, M., Savinainen, J. R., and Laitinen,
J. T. (2014). Brain regional cannabinoid CB(1) receptor signalling and alterna-
tive enzymatic pathways for 2-arachidonoylglycerol generation in brain sections
of diacylglycerol lipase deﬁcient mice. Eur. J. Pharm. Sci. 51, 87–95. doi:
10.1016/j.ejps.2013.08.035
Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., et al.
(2007). Cannabinoidsmediate analgesia largely via peripheral type 1 cannabinoid
receptors in nociceptors. Nat. Neurosci. 10, 870–879. doi: 10.1038/nn1916
Ahn, K., Mckinney, M. K., and Cravatt, B. F. (2008). Enzymatic pathways that
regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108, 1687–
1707. doi: 10.1021/cr0782067
Ansonoff, M. A., Zhang, J., Czyzyk, T., Rothman, R. B., Stewart, J., Xu, H., et al.
(2006). Antinociceptive and hypothermic effects of salvinorin a are abolished in a
novel strain of kappa-opioid receptor-1 knockout mice. J. Pharmacol. Exp. Ther.
318, 641–648. doi: 10.1124/jpet.106.101998
Belin, D., and Deroche-Gamonet, V. (2012). Responses to novelty and vul-
nerability to cocaine addiction: contribution of a multi-symptomatic animal
model. Cold Spring Harb. Perspect. Med. 2:a011940. doi: 10.1101/cshperspect.a0
11940.
Bellocchio, L., Lafenetre, P., Cannich, A., Cota, D., Puente, N., Grandes, P., et al.
(2010). Bimodal control of stimulated food intake by the endocannabinoid
system. Nat. Neurosci. 13, 281–283. doi: 10.1038/nn.2494
Bellocchio, L., Soria-Gomez, E., Quarta, C., Metna-Laurent, M., Cardinal, P.,
Binder, E., et al. (2013). Activation of the sympathetic nervous system medi-
ates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc. Natl.
Acad. Sci. U.S.A. 110, 4786–4791. doi: 10.1073/pnas.1218573110
Berrendero, F., Mendizabal, V., Murtra, P., Kieffer, B. L., and Maldonado, R. (2003).
Cannabinoid receptor andWIN55 212-2-stimulated [35S]-GTPgammaS binding
in the brain of mu-, delta-, and kappa-opioid receptor knockout mice. Eur. J.
Neurosci. 18, 2197–2202. doi: 10.1046/j.1460-9568.2003.02951.x
Bodnar, R. J. (2014). Endogenous opiates and behavior: 2013. Peptides 62C, 67–136.
doi: 10.1016/j.peptides.2014.09.013
Brady, L. S., Herkenham, M., Rothman, R. B., Partilla, J. S., Konig, M., Zimmer,
A. M., et al. (1999). Region-speciﬁc up-regulation of opioid receptor binding
in enkephalin knockout mice. Brain Res. Mol. Brain Res. 68, 193–197. doi:
10.1016/S0169-328X(99)00090-X
Buckley, N. E., Mccoy, K. L., Mezey, E., Bonner, T., Zimmer, A., Felder, C. C.,
et al. (2000). Immunomodulation by cannabinoids is absent in mice deﬁcient
for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396, 141–149. doi:
10.1016/S0014-2999(00)00211-9
Frontiers in Pharmacology | Neuropharmacology February 2015 | Volume 6 | Article 6 | 10
Befort Opioid and cannabinoid systems interaction in reward
Bushlin, I., Gupta, A., Stockton, S. D. Jr., Miller, L. K., and Devi, L. A.
(2012). Dimerization with cannabinoid receptors allosterically modulates delta
opioid receptor activity during neuropathic pain. PLoS ONE 7:e49789. doi:
10.1371/journal.pone.0049789
Castane, A., Robledo, P., Matifas, A., Kieffer, B. L., and Maldonado, R. (2003).
Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid
receptor knockout mice. Eur. J. Neurosci. 17, 155–159. doi: 10.1046/j.1460-
9568.2003.02409.x
Chanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P., et al.
(2010). Monoacylglycerol lipase activity is a critical modulator of the tone and
integrity of the endocannabinoid system. Mol. Pharmacol. 78, 996–1003. doi:
10.1124/mol.110.068304
Charbogne, P., Kieffer, B. L., and Befort, K. (2014). 15 years of genetic approaches
in vivo for addiction research: opioid receptor and peptide gene knockout
in mouse models of drug abuse. Neuropharmacology 76(Pt B), 204–217. doi:
10.1016/j.neuropharm.2013.08.028
Chu Sin Chung, P., Keyworth, H. L., Martin-Garcia, E., Charbogne, P., Darcq,
E., Bailey, A., et al. (2014). A novel anxiogenic role for the delta opioid
receptor expressed in GABAergic forebrain neurons. Biol. Psychiatry doi:
10.1016/j.biopsych.2014.07.033 [Epub ahead of print].
Clarke, S.,Czyzyk,T.,Ansonoff,M.,Nitsche, J. F.,Hsu,M. S.,Nilsson, L., et al. (2002).
Autoradiography of opioid and ORL1 ligands in opioid receptor triple knockout
mice. Eur. J. Neurosci. 16, 1705–1712. doi: 10.1046/j.1460-9568.2002.02239.x
Clarke, S., Zimmer, A., Zimmer, A. M., Hill, R. G., and Kitchen, I. (2003). Region
selective up-regulation of micro-, delta- and kappa-opioid receptors but not opi-
oid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout
mice. Neuroscience 122, 479–489. doi: 10.1016/j.neuroscience.2003.07.011
Contet, C., Kieffer, B. L., andBefort, K. (2004). Muopioid receptor: a gateway to drug
addiction. Curr. Opin. Neurobiol. 14, 370–378. doi: 10.1016/j.conb.2004.05.005
Cossu, G., Ledent, C., Fattore, L., Imperato, A., Bohme, G. A., Parmentier, M.,
et al. (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer
morphine but not other drugs of abuse. Behav. Brain Res. 118, 61–65. doi:
10.1016/S0166-4328(00)00311-9
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin,
B. R., et al. (2001). Supersensitivity to anandamide and enhanced endogenous
cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl.
Acad. Sci. U.S.A. 98, 9371–9376. doi: 10.1073/pnas.161191698
Cravatt, B. F., Giang,D. K.,Mayﬁeld, S. P., Boger,D. L., Lerner, R.A., andGilula,N. B.
(1996). Molecular characterization of an enzyme that degrades neuromodulatory
fatty-acid amides. Nature 384, 83–87. doi: 10.1038/384083a0
Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., and
Lichtman, A. H. (2004). Functional disassociation of the central and peripheral
fatty acid amide signaling systems. Proc. Natl. Acad. Sci. U.S.A. 101, 10821–10826.
doi: 10.1073/pnas.0401292101
Cui, Y., Ostlund, S. B., James, A. S., Park, C. S., Ge, W., Roberts, K. W., et al. (2014).
Targeted expression of mu-opioid receptors in a subset of striatal direct-pathway
neurons restores opiate reward. Nat. Neurosci. 17, 254–261. doi: 10.1038/n
n.3622
D’Addario, C., Di Francesco, A., Pucci, M., Finazzi Agro, A., and Maccarrone, M.
(2013). Epigenetic mechanisms and endocannabinoid signalling. FEBS J. 280,
1905–1917. doi: 10.1111/febs.12125
De Luca, M. A., Valentini, V., Bimpisidis, Z., Cacciapaglia, F., Caboni, P., and Di
Chiara, G. (2014). Endocannabinoid 2-arachidonoylglycerol self-administration
by sprague-dawley rats and stimulation of in vivo dopamine transmission in the
nucleus accumbens Shell. Front. Psychiatry 5:140. doi: 10.3389/fpsyt.2014.00140
De Petrocellis, L., and Di Marzo, V. (2010). Non-CB1, non-CB2 receptors
for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics:
focus on G-protein-coupled receptors and transient receptor potential channels.
J. Neuroimmune Pharmacol. 5, 103–121. doi: 10.1007/s11481-009-9177-z
Dhopeshwarkar, A., and Mackie, K. (2014). CB2 cannabinoid receptors as a ther-
apeutic target-what does the future hold? Mol. Pharmacol. 86, 430–437. doi:
10.1124/mol.114.094649
Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M.,
et al. (2000). Levels, metabolism, and pharmacological activity of anandamide
in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-
CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem.
75, 2434–2444. doi: 10.1046/j.1471-4159.2000.0752434.x
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., et al.
(2002). Brain monoglyceride lipase participating in endocannabinoid inactiva-
tion. Proc. Natl. Acad. Sci. U.S.A. 99, 10819–10824. doi: 10.1073/pnas.152334899
Dubreucq, S., Kambire, S., Conforzi, M., Metna-Laurent, M., Cannich, A., Soria-
Gomez, E., et al. (2012a). Cannabinoid type 1 receptors located on single-minded
1-expressing neurons control emotional behaviors. Neuroscience 204, 230–244.
doi: 10.1016/j.neuroscience.2011.08.049
Dubreucq, S., Matias, I., Cardinal, P., Haring, M., Lutz, B., Marsicano, G., et al.
(2012b). Genetic dissection of the role of cannabinoid type-1 receptors in the
emotional consequences of repeated social stress in mice. Neuropsychopharma-
cology 37, 1885–1900. doi: 10.1038/npp.2012.36
Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J. L., et al. (2014). A
mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical
networks. Brain Struct. Funct. doi: 10.1007/s00429-014-0717-9 [Epub ahead of
print].
Evans, C. J., Keith, D. E. Jr., Morrison, H., Magendzo, K., and Edwards, R. H.
(1992). Cloning of a delta opioid receptor by functional expression. Science 258,
1952–1955. doi: 10.1126/science.1335167
Everitt, B. J., and Robbins, T. W. (2005). Neural systems of reinforcement for drug
addiction: from actions to habits to compulsion. Nat. Neurosci. 8, 1481–1489.
doi: 10.1038/nn1579
Fattore, L., Cossu, G., Martellotta, C. M., and Fratta, W. (2001). Intravenous self-
administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Psychopharmacology (Berl) 156, 410–416. doi: 10.1007/s002130100734
Fattore, L., Deiana, S., Spano, S. M., Cossu, G., Fadda, P., Scherma, M., et al. (2005).
Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol.
Biochem. Behav. 81, 343–359. doi: 10.1016/j.pbb.2005.01.031
Fattore, L., and Fratta,W. (2011). Beyond THC: the new generation of cannabinoid
designer drugs. Front. Behav. Neurosci. 5:60. doi: 10.3389/fnbeh.2011.00060
Fernandez-Ruiz, J., Hernandez, M., and Ramos, J. A. (2010). Cannabinoid-
dopamine interaction in the pathophysiology and treatment of CNS disorders.
CNS Neurosci. Ther. 16, e72–e91. doi: 10.1111/j.1755-5949.2010.00144.x
Ferre, S., Lluis, C., Justinova, Z., Quiroz, C., Orru, M., Navarro, G., et al. (2010).
Adenosine-cannabinoid receptor interactions. Implications for striatal function.
Br. J. Pharmacol. 160, 443–453. doi: 10.1111/j.1476-5381.2010.00723.x
Filizola, M., and Devi, L. A. (2014). Grand opening of structure-guided design for
novel opioids. Trends Pharmacol. Sci. 34, 6–12. doi: 10.1016/j.tips.2012.10.002
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W., Simonin, F.,
et al. (2000). Mice deﬁcient for delta- and mu-opioid receptors exhibit opposing
alterations of emotional responses. Nat. Genet. 25, 195–200. doi: 10.1038/76061
Flores, A., Maldonado, R., and Berrendero, F. (2014). The hypocretin/orexin
receptor-1 as a novel target to modulate cannabinoid reward. Biol. Psychiatry
75, 499–507. doi: 10.1016/j.biopsych.2013.06.012
Fowler, C. D., and Kenny, P. J. (2012). Utility of genetically modiﬁed mice for
understanding the neurobiology of substance use disorders. Hum. Genet. 131,
941–957. doi: 10.1007/s00439-011-1129-z
Fratta,W., and Fattore, L. (2013). Molecular mechanisms of cannabinoid addiction.
Curr. Opin. Neurobiol. 23, 487–492. doi: 10.1016/j.conb.2013.02.002
Frazier, C. J. (2011). Key questions of endocannabinoid signalling in theCNS:which,
where and when? J. Physiol. 589, 4807–4808. doi: 10.1113/jphysiol.2011.219493
Fujita, W., Gomes, I., and Devi, L. A. (2014). Revolution in GPCR signalling:
opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br.
J. Pharmacol. 171, 4155–4176. doi: 10.1111/bph.12798
Gaffal, E., Cron, M., Glodde, N., Bald, T., Kuner, R., Zimmer, A., et al. (2013).
Cannabinoid 1 receptors in keratinocytes modulate proinﬂammatory chemokine
secretion and attenuate contact allergic inﬂammation. J. Immunol. 190, 4929–
4936. doi: 10.4049/jimmunol.1201777
Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M.,
et al. (2010). Loss of retrograde endocannabinoid signaling and reduced adult
neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30, 2017–2024.
doi: 10.1523/JNEUROSCI.5693-09.2010
Gardner, E. L. (2005). Endocannabinoid signaling system and brain reward:
emphasis on dopamine. Pharmacol. Biochem. Behav. 81, 263–284. doi:
10.1016/j.pbb.2005.01.032
Gaveriaux-Ruff, C. (2013). Opiate-induced analgesia: contributions from mu, delta
and kappa opioid receptors mouse mutants. Curr. Pharm. Des 19, 7373–7381.
doi: 10.2174/138161281942140105163727
www.frontiersin.org February 2015 | Volume 6 | Article 6 | 11
Befort Opioid and cannabinoid systems interaction in reward
Gaveriaux-Ruff, C., Nozaki, C., Nadal, X., Hever, X. C., Weibel, R., Matifas, A., et al.
(2011). Genetic ablation of delta opioid receptors in nociceptive sensory neurons
increases chronic pain and abolishes opioid analgesia. Pain 152, 1238–1248. doi:
10.1016/j.pain.2010.12.031
Gerald, T. M., Howlett, A. C., Ward, G. R., Ho, C., and Franklin, S. O. (2008).
Gene expression of opioid and dopamine systems in mouse striatum: effects
of CB1 receptors, age and sex. Psychopharmacology (Berl.) 198, 497–508. doi:
10.1007/s00213-008-1141–1148
Gerald, T. M., Ward, G. R., Howlett, A. C., and Franklin, S. O. (2006).
CB1 knockout mice display signiﬁcant changes in striatal opioid peptide
and D4 dopamine receptor gene expression. Brain Res. 1093, 20–24. doi:
10.1016/j.brainres.2006.03.088
Ghozland, S., Matthes, H. W., Simonin, F., Filliol, D., Kieffer, B. L., and Maldonado,
R. (2002). Motivational effects of cannabinoids are mediated by mu-opioid and
kappa-opioid receptors. J. Neurosci. 22, 1146–1154.
Gong, J. P., Onaivi, E. S., Ishiguro, H., Liu, Q. R., Tagliaferro, P. A., Brusco, A.,
et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in
rat brain. Brain Res. 1071, 10–23. doi: 10.1016/j.brainres.2005.11.035
Goody, R. J., Oakley, S. M., Filliol, D., Kieffer, B. L., and Kitchen, I.
(2002). Quantitative autoradiographic mapping of opioid receptors in the
brain of delta-opioid receptor gene knockout mice. Brain Res. 945, 9–19. doi:
10.1016/S0006-8993(02)02452-6
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., et al.
(2011). Cost of disorders of the brain inEurope 2010. Eur. Neuropsychopharmacol.
21, 718–779. doi: 10.1016/j.euroneuro.2011.08.008
Gutierrez-Cuesta, J., Burokas, A., Mancino, S., Kummer, S., Martin-Garcia, E.,
and Maldonado, R. (2014). Effects of genetic deletion of endogenous opioid
system components on the reinstatement of cocaine-seeking behavior in mice.
Neuropsychopharmacology. doi: 10.1038/npp.2014.149
Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F.,
et al. (2012). Acute cannabinoids impair working memory through astroglial
CB1 receptor modulation of hippocampal LTD. Cell 148, 1039–1050. doi:
10.1016/j.cell.2012.01.037
Hough, L. B., Nalwalk, J. W., Chen, Y., Schuller, A., Zhu, Y., Zhang, J.,
et al. (2000). Improgan, a cimetidine analog, induces morphine-like antinoci-
ception in opioid receptor-knockout mice. Brain Res. 880, 102–108. doi:
10.1016/S0006-8993(00)02776-1
Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., and Damaj, M. I.
(2013). The cannabinoidCB2 receptor is necessary for nicotine-conditionedplace
preference, but not other behavioral effects of nicotine in mice. Psychopharma-
cology (Berl) 229, 591–601. doi: 10.1007/s00213-013-3117-6
Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., et al.
(1999). Cannabinoid-induced mesenteric vasodilation through an endothelial
site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 96, 14136–
14141. doi: 10.1073/pnas.96.24.14136
Jeong, W. I., Osei-Hyiaman, D., Park, O., Liu, J., Batkai, S., Mukhopadhyay, P.,
et al. (2008). Paracrine activation of hepatic CB1 receptors by stellate cell-derived
endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7, 227–235. doi:
10.1016/j.cmet.2007.12.007
Kieffer, B. L. (1995). Recent advances in molecular recognition and signal trans-
duction of active peptides: receptors for opioid peptides. Cell Mol. Neurobiol. 15,
615–635. doi: 10.1007/BF02071128
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., and Hirth, C. G. (1992). The
delta-opioid receptor: isolation of a cDNA by expression cloning and pharma-
cological characterization. Proc. Natl. Acad. Sci. U.S.A. 89, 12048–12052. doi:
10.1073/pnas.89.24.12048
Kieffer, B. L., and Gaveriaux-Ruff, C. (2002). Exploring the opioid system by gene
knockout. Prog. Neurobiol. 66, 285–306. doi: 10.1016/S0301-0082(02)00008-4
Kitchen, I., Slowe, S. J., Matthes, H. W., and Kieffer, B. (1997). Quantitative
autoradiographic mapping of mu-, delta-, and kappa-opioid receptors in knock-
out mice lacking the mu-opioid receptor gene. Brain Res. 778, 73–88. doi:
10.1016/S0006-8993(97)00988-8
Konig, M., Zimmer, A. M., Steiner, H., Holmes, P. V., Crawley, J. N., Brownstein,
M. J., et al. (1996). Pain responses, anxiety and aggression in mice deﬁcient in
pre-proenkephalin. Nature 383, 535–538. doi: 10.1038/383535a0
Koob, G. F. (2009). Neurobiological substrates for the dark side of com-
pulsivity in addiction. Neuropharmacology 56(Suppl. 1), 18–31. doi:
10.1016/j.neuropharm.2008.07.043
Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsy-
chopharmacology 35, 217–238. doi: 10.1038/npp.2009.110
Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., and Butelman,
E. R. (2012). Opiate addiction and cocaine addiction: underlying molecular
neurobiology and genetics. J. Clin. Invest. 122, 3387–3393. doi: 10.1172/JCI60390
Le Merrer, J., Becker, J. A., Befort, K., and Kieffer, B. L. (2009). Reward pro-
cessing by the opioid system in the brain. Physiol. Rev. 89, 1379–1412. doi:
10.1152/physrev.00005.2009
Le Naour, M., Akgun, E., Yekkirala, A., Lunzer, M. M., Powers, M. D., Kalyuzhny,
A. E., et al. (2013). Bivalent ligands that target mu opioid (MOP) and cannabi-
noid1 (CB1) receptors are potent analgesics devoid of tolerance. J. Med. Chem.
56, 5505–5513. doi: 10.1021/jm4005219
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., et al. (1999).
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in
CB1 receptor knockout mice. Science 283, 401–404. doi: 10.1126/science.283.54
00.401
Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science 278, 45–47.
doi: 10.1126/science.278.5335.45
Leung, D., Saghatelian, A., Simon, G. M., and Cravatt, B. F. (2006). Inactivation
of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mecha-
nisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720–4726.
doi: 10.1021/bi060163l
Lichtman, A. H., Sheikh, S. M., Loh, H. H., and Martin, B. R. (2001).
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-
tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther.
298, 1007–1014.
Liu, J., Wang, L., Harvey-White, J., Huang, B. X., Kim, H. Y., Luquet, S.,
et al. (2008). Multiple pathways involved in the biosynthesis of anandamide.
Neuropharmacology 54, 1–7. doi: 10.1016/j.neuropharm.2007.05.020
Loacker, S., Sayyah, M., Wittmann, W., Herzog, H., and Schwarzer, C. (2007).
Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net
effect via kappa opioid receptors. Brain 130, 1017–1028. doi: 10.1093/brain/
awl384
Loh, H. H., Liu, H. C., Cavalli, A., Yang, W., Chen, Y. F., and Wei, L. N. (1998).
mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and
morphine lethality. Brain Res. Mol. Brain Res. 54, 321–326. doi: 10.1016/S0169-
328X(97)00353-7
Lopez-Moreno, J. A., Lopez-Jimenez,A., Gorriti,M.A., andDe Fonseca, F. R. (2010).
Functional interactions between endogenous cannabinoid and opioid systems:
focus on alcohol, genetics and drug-addicted behaviors. Curr. Drug Targets 11,
406–428. doi: 10.2174/138945010790980312
Lutz, P. E., Ayranci, G., Chu-Sin-Chung, P., Matifas, A., Koebel, P., Filliol,
D., et al. (2014). Distinct mu, delta, and kappa opioid receptor mechanisms
underlie low sociability and depressive-like behaviors during heroin abstinence.
Neuropsychopharmacology 39, 2694–2705. doi: 10.1038/npp.2014.126
Lutz, P. E., and Kieffer, B. L. (2013a). The multiple facets of opioid receptor
function: implications for addiction. Curr. Opin. Neurobiol. 23, 473–479. doi:
10.1016/j.conb.2013.02.005
Lutz, P. E., and Kieffer, B. L. (2013b). Opioid receptors: distinct roles in
mood disorders. Trends Neurosci. 36, 195–206. doi: 10.1016/j.tins.2012.
11.002
Maccarrone, M., Attina, M., Bari, M., Cartoni, A., Ledent, C., and Finazzi-Agro,
A. (2001). Anandamide degradation and N-acylethanolamines level in wild-type
and CB1 cannabinoid receptor knockout mice of different ages. J. Neurochem. 78,
339–348. doi: 10.1046/j.1471-4159.2001.00413.x
Maccarrone, M., Valverde, O., Barbaccia, M. L., Castane, A., Maldonado, R., Ledent,
C., et al. (2002). Age-related changes of anandamide metabolism in CB1 cannabi-
noid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15,
1178–1186. doi: 10.1046/j.1460-9568.2002.01957.x
Mackie, K. (2005). Distribution of cannabinoid receptors in the central and
peripheral nervous system. Handb. Exp. Pharmacol. 299–325.
Mackie, K. (2008). Cannabinoid receptors: where they are and what they do.
J. Neuroendocrinol. 20(Suppl. 1), 10–14. doi: 10.1111/j.1365-2826.2008.01671.x
Maldonado, R. (2002). Study of cannabinoid dependence in animals. Pharmacol.
Ther. 95, 153–164. doi: 10.1016/S0163-7258(02)00254-1
Maldonado, R., Berrendero, F., Ozaita, A., and Robledo, P. (2011). Neu-
rochemical basis of cannabis addiction. Neuroscience 181, 1–17. doi:
10.1016/j.neuroscience.2011.02.035
Frontiers in Pharmacology | Neuropharmacology February 2015 | Volume 6 | Article 6 | 12
Befort Opioid and cannabinoid systems interaction in reward
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J.,
et al. (1996). Reduction of morphine abstinence in mice with a mutation in
the gene encoding CREB. Science 273, 657–659. doi: 10.1126/science.273.527
5.657
Maldonado, R., Robledo, P., and Berrendero, F. (2013). Endocannabinoid system
and drug addiction: new insights from mutant mice approaches. Curr. Opin.
Neurobiol. 23, 480–486. doi: 10.1016/j.conb.2013.02.004
Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement of the
endocannabinoid system in drug addiction. Trends Neurosci. 29, 225–232. doi:
10.1016/j.tins.2006.01.008
Mansour, A., Fox, C. A., Akil, H., and Watson, S. J. (1995). Opioid-receptor
mRNA expression in the rat CNS: anatomical and functional implications. Trends
Neurosci. 18, 22–29. doi: 10.1016/0166-2236(95)93946-U
Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J. J., Ramos, J. A.,
and Fuentes, J. A. (1999). Pharmacological and biochemical interactions
between opioids and cannabinoids. Trends Pharmacol. Sci. 20, 287–294. doi:
10.1016/S0165-6147(99)01339-5
Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver,
L. P., et al. (2007). Direct suppression of CNS autoimmune inﬂammation via the
cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med.
13, 492–497. doi: 10.1038/nm1561
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich,
A., et al. (2003). CB1 cannabinoid receptors and on-demand defense against
excitotoxicity. Science 302, 84–88. doi: 10.1126/science.1088208
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G.,
et al. (2002). The endogenous cannabinoid system controls extinction of aversive
memories. Nature 418, 530–534. doi: 10.1038/nature00839
Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., and Fratta, W. (1998). Self-
administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive
mice. Neuroscience 85, 327–330. doi: 10.1016/S0306-4522(98)00052-9
Martin, M., Ledent, C., Parmentier, M., Maldonado, R., and Valverde, O. (2000).
Cocaine, but not morphine, induces conditioned place preference and sensi-
tization to locomotor responses in CB1 knockout mice. Eur. J. Neurosci. 12,
4038–4046. doi: 10.1046/j.1460-9568.2000.00287.x
Mascia, M. S., Obinu, M. C., Ledent, C., Parmentier, M., Bohme, G. A., Imperato,
A., et al. (1999). Lack of morphine-induced dopamine release in the nucleus
accumbens of cannabinoid CB(1) receptor knockout mice. Eur. J. Pharmacol 383,
R1–R2. doi: 10.1016/S0014-2999(99)00656-1
Massotte, D. (2014). In vivo opioid receptor heteromerization: where do we stand?
Br. J. Pharmacol. 172, 420–434. doi: 10.1111/bph.12702
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I.
(1990). Structure of a cannabinoid receptor and functional expression of the
cloned cDNA. Nature 346, 561–564. doi: 10.1038/346561a0
Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I.,
et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal
symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819–823.
doi: 10.1038/383819a0
Mendizabal, V., Zimmer, A., and Maldonado, R. (2006). Involvement of
kappa/dynorphin system inWIN55,212-2 self-administration inmice. Neuropsy-
chopharmacology 31, 1957–1966. doi: 10.1038/sj.npp.1300957
Mestek, A., Hurley, J. H., Bye, L. S., Campbell, A. D., Chen, Y., Tian, M., et al. (1995).
The human mu opioid receptor: modulation of functional desensitization by
calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci.
15, 2396–2406.
Mizoguchi, H., Watanabe, C., Osada, S., Yoshioka, M., Aoki, Y., Natsui, S., et al.
(2010). Lack of a rewarding effect and a locomotor-enhancing effect of the selec-
tive mu-opioid receptor agonist amidino-TAPA. Psychopharmacology (Berl) 212,
215–225. doi: 10.1007/s00213-010-1946-0
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schutz, G.,
et al. (2007). Genetic dissection of behavioural and autonomic effects of
Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 5:e269. doi: 10.1371/jour-
nal.pbio.0050269
Monory, K., Massa, F., Egertova, M., Eder, M., Blaudzun, H., Westenbroek, R., et al.
(2006). The endocannabinoid system controls key epileptogenic circuits in the
hippocampus. Neuron 51, 455–466. doi: 10.1016/j.neuron.2006.07.006
Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization
of a peripheral receptor for cannabinoids. Nature 365, 61–65. doi: 10.1038/
365061a0
Nadal, X., La Porta, C., Andreea Bura, S., and Maldonado, R. (2013). Involve-
ment of the opioid and cannabinoid systems in pain control: new insights from
knockout studies. Eur. J. Pharmacol. 716, 142–157. doi: 10.1016/j.ejphar.2013.
01.077
Navarrete, F., Rodriguez-Arias, M., Martin-Garcia, E., Navarro, D., Garcia-
Gutierrez, M. S., Aguilar, M. A., et al. (2013). Role of CB2 cannabinoid
receptors in the rewarding, reinforcing, and physical effects of nicotine.
Neuropsychopharmacology 38, 2515–2524. doi: 10.1038/npp.2013.157
Nestler, E. J. (2014). Epigenetic mechanisms of drug addiction. Neuropharmacology
76 Pt B, 259–268. doi: 10.1016/j.neuropharm.2013.04.004
Niikura, K., Narita, M., Okutsu, D., Tsurukawa, Y., Nanjo, K., Kurahashi, K.,
et al. (2008). Implication of endogenous beta-endorphin in the inhibition of
the morphine-induced rewarding effect by the direct activation of spinal protein
kinase C in mice. Neurosci. Lett. 433, 54–58. doi: 10.1016/j.neulet.2007.12.042
Nogueiras, R., Romero-Pico, A., Vazquez, M. J., Novelle, M. G., Lopez, M., and
Dieguez, C. (2014). The opioid system and food intake: homeostatic and hedonic
mechanisms. Obes. Facts 5, 196–207. doi: 10.1159/000338163
Oakley, S. M., Toth, G., Borsodi, A., Kieffer, B. L., and Kitchen, I. (2003). G-protein
coupling of delta-opioid receptors in brains of mu-opioid receptor knockout
mice. Eur. J. Pharmacol. 466, 91–98. doi: 10.1016/S0014-2999(03)01531-0
Ohno-Shosaku, T., and Kano, M. (2014). Endocannabinoid-mediated retrograde
modulation of synaptic transmission. Curr. Opin. Neurobiol. 29C, 1–8. doi:
10.1016/j.conb.2014.03.017
Onaivi, E. S., Ishiguro, H., Gong, J. P., Patel, S., Perchuk, A., Meozzi, P. A.,
et al. (2006). Discovery of the presence and functional expression of cannabi-
noid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 1074, 514–536. doi:
10.1196/annals.1369.052
Ortega-Alvaro, A., Ternianov, A., Aracil-Fernandez, A., Navarrete, F., Garcia-
Gutierrez, M. S., and Manzanares, J. (2013). Role of cannabinoid CB receptor
in the reinforcing actions of ethanol. Addict. Biol. doi: 10.1111/adb.12076
Pan, Y. X., Xu, J., Xu, M., Rossi, G. C., Matulonis, J. E., and Pasternak, G. W. (2009).
Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in
heroin, but not morphine, actions. Proc. Natl. Acad. Sci. U.S.A. 106, 4917–4922.
doi: 10.1073/pnas.0811586106
Panagis, G., Mackey, B., and Vlachou, S. (2014). Cannabinoid regulation of brain
reward processing with an emphasis on the role of CB1 receptors: a step back into
the future. Front. Psychiatry 5:92. doi: 10.3389/fpsyt.2014.00092
Panlilio, L. V., and Goldberg, S. R. (2007). Self-administration of drugs in animals
and humans as a model and an investigative tool. Addiction 102, 1863–1870. doi:
10.1111/j.1360-0443.2007.02011.x
Panlilio, L. V., Justinova, Z., and Goldberg, S. R. (2010). Animal models of
cannabinoid reward. Br. J. Pharmacol. 160, 499–510. doi: 10.1111/j.1476-
5381.2010.00775.x
Parolaro, D., Rubino, T., Vigano, D., Massi, P., Guidali, C., and Realini, N. (2010).
Cellular mechanisms underlying the interaction between cannabinoid and opioid
system. Curr. Drug Targets 11, 393–405. doi: 10.2174/138945010790980367
Pattij, T., and De Vries, T. J. (2013). The role of impulsivity in relapse vulnerability.
Curr. Opin. Neurobiol. 23, 700–705. doi: 10.1016/j.conb.2013.01.023
Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabi-
noid receptor agonists and antagonists. Curr. Med. Chem 17, 1360–1381. doi:
10.2174/092986710790980050
Petrenko, A. B., Yamazaki, M., Sakimura, K., Kano, M., and Baba, H.
(2014). Augmented tonic pain-related behavior in knockout mice lack-
ing monoacylglycerol lipase, a major degrading enzyme for the endo-
cannabinoid 2-arachidonoylglycerol. Behav. Brain Res. 271, 51–58. doi:
10.1016/j.bbr.2014.05.063
Piomelli, D. (2014). More surprises lying ahead. The endocannabi-
noids keep us guessing. Neuropharmacology 76 Pt B, 228–234. doi:
10.1016/j.neuropharm.2013.07.026
Pol, O., Murtra, P., Caracuel, L., Valverde, O., Puig, M. M., and Maldonado,
R. (2006). Expression of opioid receptors and c-fos in CB1 knockout mice
exposed to neuropathic pain. Neuropharmacology 50, 123–132. doi: 10.1016/j.
neuropharm.2005.11.002
Pradhan, A. A., Befort, K., Nozaki, C., Gaveriaux-Ruff, C., and Kieffer, B. L. (2011).
The delta opioid receptor: an evolving target for the treatment of brain disorders.
Trends Pharmacol. Sci. 32, 581–590. doi: 10.1016/j.tips.2011.06.008
Pryce, G., Visintin, C., Ramagopalan, S. V., Al-Izki, S., De Faveri, L. E., Nuamah,
R. A., et al. (2014). Control of spasticity in a multiple sclerosis model using
www.frontiersin.org February 2015 | Volume 6 | Article 6 | 13
Befort Opioid and cannabinoid systems interaction in reward
central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J.
28, 117–130. doi: 10.1096/fj.13–239442
Ragnauth, A., Schuller, A., Morgan, M., Chan, J., Ogawa, S., Pintar, J., et al. (2001).
Female preproenkephalin-knockout mice display altered emotional responses.
Proc. Natl. Acad. Sci. U.S.A. 98, 1958–1963. doi: 10.1073/pnas.041598498
Ramesh, D., Gamage, T. F., Vanuytsel, T., Owens, R. A., Abdullah, R. A.,
Niphakis, M. J., et al. (2013). Dual inhibition of endocannabinoid catabolic
enzymes produces enhanced antiwithdrawal effects in morphine-dependent
mice. Neuropsychopharmacology 38, 1039–1049. doi: 10.1038/npp.2012.269
Ramesh, D., Ross, G. R., Schlosburg, J. E., Owens, R. A., Abdullah, R. A., Kinsey,
S. G., et al. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates
precipitated opioid withdrawal symptoms in mice. J. Pharmacol. Exp. Ther. 339,
173–185. doi: 10.1124/jpet.111.181370
Rice, O. V., Gordon, N., and Gifford, A. N. (2002). Conditioned place preference to
morphine in cannabinoid CB1 receptor knockout mice. Brain Res. 945, 135–138.
doi: 10.1016/S0006-8993(02)02890-1
Robbe, D., Kopf, M., Remaury, A., Bockaert, J., and Manzoni, O. J. (2002). Endoge-
nous cannabinoids mediate long-term synaptic depression in the nucleus accum-
bens. Proc. Natl. Acad. Sci. U.S.A. 99, 8384–8388. doi: 10.1073/pnas.122149199
Robinson, T. E., and Berridge, K. C. (2008). Review. The incentive sensitization
theory of addiction: some current issues. Philos. Trans. R. Soc. Lond. B Biol. Sci.
363, 3137–3146. doi: 10.1098/rstb.2008.0093
Robledo, P., Berrendero, F., Ozaita, A., and Maldonado, R. (2008). Advances
in the ﬁeld of cannabinoid–opioid cross-talk. Addict. Biol. 13, 213–224. doi:
10.1111/j.1369-1600.2008.00107.x
Roques, B. P., Fournie-Zaluski, M. C., and Wurm, M. (2012). Inhibiting the break-
down of endogenous opioids and cannabinoids to alleviate pain. Nat. Rev. Drug
Discov. 11, 292–310. doi: 10.1038/nrd3673
Rubinstein, M., Mogil, J. S., Japon, M., Chan, E. C., Allen, R. G., and Low,
M. J. (1996). Absence of opioid stress-induced analgesia in mice lacking beta-
endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 93,
3995–4000. doi: 10.1073/pnas.93.9.3995
Ruehle, S., Remmers, F., Romo-Parra, H., Massa, F., Wickert, M., Wortge, S.,
et al. (2013). Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic
neurons: distinctive sufﬁciency for hippocampus-dependent and amygdala-
dependent synaptic and behavioral functions. J. Neurosci. 33, 10264–10277. doi:
10.1523/JNEUROSCI.4171-12.2013
Sanchis-Segura, C., Cline, B. H., Marsicano, G., Lutz, B., and Spanagel, R. (2004).
Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl)
176, 223–232. doi: 10.1007/s00213-004-1877–1878
Sanchis-Segura, C., and Spanagel, R. (2006). Behavioural assessment of drug rein-
forcement and addictive features in rodents: an overview. Addict. Biol. 11, 2–38.
doi: 10.1111/j.1369-1600.2006.00012.x
Saunders, B. T., and Robinson, T. E. (2013). Individual variation in resisting temp-
tation: implications for addiction. Neurosci. Biobehav. Rev. 37, 1955–1975. doi:
10.1016/j.neubiorev.2013.02.008
Scavone, J. L., Sterling, R. C., and Van Bockstaele, E. J. (2013). Cannabinoid
and opioid interactions: implications for opiate dependence and withdrawal.
Neuroscience 248, 637–654. doi: 10.1016/j.neuroscience.2013.04.034
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey,
S. G., et al. (2010). Chronic monoacylglycerol lipase blockade causes functional
antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113–1119. doi:
10.1038/nn.2616
Schuller,A.G.,King,M.A., Zhang, J., Bolan, E., Pan,Y.X.,Morgan,D. J., et al. (1999).
Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of
mice lacking exon 1 of MOR-1. Nat. Neurosci. 2, 151–156. doi: 10.1038/5706
Shariﬁ, N., Diehl, N., Yaswen, L., Brennan, M. B., and Hochgeschwender, U. (2001).
Generation of dynorphin knockout mice. Brain Res. Mol. Brain Res. 86, 70–75.
doi: 10.1016/S0169-328X(00)00264-3
Simonin, F., Befort, K., Gaveriaux-Ruff, C., Matthes, H., Nappey,V., Lannes, B., et al.
(1994). The human delta-opioid receptor: genomic organization, cDNA cloning,
functional expression, and distribution in human brain. Mol. Pharmacol. 46,
1015–1021.
Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti,
G., et al. (1995). kappa-Opioid receptor in humans: cDNA and genomic cloning,
chromosomal assignment, functional expression, pharmacology, and expression
pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 92, 7006–7010.
doi: 10.1073/pnas.92.15.7006
Simonin, F., Slowe, S., Becker, J. A., Matthes, H. W., Filliol, D., Chluba, J., et al.
(2001). Analysis of [3H]bremazocine binding in single and combinatorial opioid
receptor knockout mice. Eur. J. Pharmacol. 414, 189–195. doi: 10.1016/S0014-
2999(01)00822-6
Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., et al. (1998).
Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to
chemical visceral pain, impairs pharmacological actions of the selective kappa-
agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17, 886–897.
doi: 10.1093/emboj/17.4.886
Skoubis, P. D., Lam, H. A., Shoblock, J., Narayanan, S., and Maidment, N. T.
(2005). Endogenous enkephalins, not endorphins, modulate basal hedonic state
in mice. Eur. J. Neurosci. 21, 1379–1384. doi: 10.1111/j.1460-9568.2005.03
956.x
Slowe, S. J., Simonin, F., Kieffer, B., and Kitchen, I. (1999). Quantitative
autoradiography of mu-delta- and kappa1 opioid receptors in kappa-opioid
receptor knockout mice. Brain Res. 818, 335–345. doi: 10.1016/S0006-8993(98)0
1201-3
Solinas, M., Goldberg, S. R., and Piomelli, D. (2008). The endocannabi-
noid system in brain reward processes. Br. J. Pharmacol. 154, 369–383. doi:
10.1038/bjp.2008.130
Sora, I., Elmer, G., Funada, M., Pieper, J., Li, X. F., Hall, F. S., et al. (2001). Mu
opiate receptor gene dose effects on different morphine actions: evidence for
differential in vivo mu receptor reserve. Neuropsychopharmacology 25, 41–54.
doi: 10.1016/S0893-133X(00)00252-9
Stein, C. (2013). Opioids, sensory systems and chronic pain. Eur. J. Pharmacol. 716,
179–187. doi: 10.1016/j.ejphar.2013.01.076
Steiner, H., Bonner, T. I., Zimmer, A. M., Kitai, S. T., and Zimmer, A. (1999).
Altered gene expression in striatal projection neurons in CB1 cannabinoid
receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 5786–5790. doi:
10.1073/pnas.96.10.5786
Sun, X., Wang, H., Okabe, M., Mackie, K., Kingsley, P. J., Marnett, L. J., et al. (2009).
Genetic loss of faah compromisesmale fertility inmice. Biol. Reprod. 80, 235–242.
doi: 10.1095/biolreprod.108.072736
Swendsen, J., and Le Moal, M. (2011). Individual vulnerability to addiction. Ann.
N. Y. Acad. Sci. 1216, 73–85. doi: 10.1111/j.1749-6632.2010.05894.x
Szutorisz, H., Dinieri, J. A., Sweet, E., Egervari, G., Michaelides, M., Carter,
J. M., et al. (2014). Parental THC exposure leads to compulsive heroin-
seeking and altered striatal synaptic plasticity in the subsequent generation.
Neuropsychopharmacology 39, 1315–1323. doi: 10.1038/npp.2013.352
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe,
M., et al. (2010). The endocannabinoid 2-arachidonoylglycerol produced by dia-
cylglycerol lipase alphamediates retrograde suppression of synaptic transmission.
Neuron 65, 320–327. doi: 10.1016/j.neuron.2010.01.021
Taschler, U., Radner, F. P., Heier, C., Schreiber, R., Schweiger, M., Schoiswohl,
G., et al. (2011). Monoglyceride lipase deﬁciency in mice impairs lipolysis and
attenuates diet-induced insulin resistance. J. Biol. Chem. 286, 17467–17477. doi:
10.1074/jbc.M110.215434
Tebano, M. T., Martire, A., and Popoli, P. (2012). Adenosine A(2A)-cannabinoid
CB(1) receptor interaction: an integrative mechanism in striatal glutamater-
gic neurotransmission. Brain Res. 1476, 108–118. doi: 10.1016/j.brainres.2012.
04.051
Tian, M., Broxmeyer, H. E., Fan, Y., Lai, Z., Zhang, S., Aronica, S., et al.
(1997). Altered hematopoiesis, behavior, and sexual function in mu opioid
receptor-deﬁcient mice. J. Exp. Med. 185, 1517–1522. doi: 10.1084/jem.185.
8.1517
Tomasiewicz, H. C., Jacobs, M. M.,Wilkinson, M. B.,Wilson, S. P., Nestler, E. J., and
Hurd, Y. L. (2012). Proenkephalin mediates the enduring effects of adolescent
cannabis exposure associated with adult opiate vulnerability. Biol. Psychiatry 72,
803–810. doi: 10.1016/j.biopsych.2012.04.026
Trigo, J. M., Martin-Garcia, E., Berrendero, F., Robledo, P., and Maldonado, R.
(2010). The endogenous opioid system: a common substrate in drug addic-
tion. Drug Alcohol Depend. 108, 183–194. doi: 10.1016/j.drugalcdep.2009.
10.011
Tsuboi, K., Okamoto, Y., Ikematsu, N., Inoue, M., Shimizu, Y., Uyama, T., et al.
(2011). Enzymatic formation of N-acylethanolamines from N-acylethanolamine
plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholi-
pase D-dependent and -independent pathways. Biochim. Biophys. Acta 1811,
565–577. doi: 10.1016/j.bbalip.2011.07.009
Frontiers in Pharmacology | Neuropharmacology February 2015 | Volume 6 | Article 6 | 14
Befort Opioid and cannabinoid systems interaction in reward
Tzschentke, T. M. (2007). Measuring reward with the conditioned place prefer-
ence (CPP) paradigm: update of the last decade. Addict. Biol. 12, 227–462. doi:
10.1111/j.1369-1600.2007.00070.x
Uchigashima, M., Yamazaki, M., Yamasaki, M., Tanimura, A., Sakimura,
K., Kano, M., et al. (2011). Molecular and morphological conﬁgura-
tion for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-
granule cell synapses in the dentate gyrus. J. Neurosci. 31, 7700–7714. doi:
10.1523/JNEUROSCI.5665-10.2011
Uriguen, L., Berrendero, F., Ledent, C., Maldonado, R., and Manzanares, J. (2005).
Kappa- and delta-opioid receptor functional activities are increased in the caudate
putamen of cannabinoid CB1 receptor knockout mice. Eur. J. Neurosci. 22, 2106–
2110. doi: 10.1111/j.1460-9568.2005.04372.x
Valverde, O., Maldonado, R., Valjent, E., Zimmer, A. M., and Zimmer, A. (2000).
Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out
mice. J. Neurosci. 20, 9284–9289.
Valverde, O., and Torrens, M. (2012). CB1 receptor-deﬁcient mice as a model
for depression. Neuroscience 204, 193–206. doi: 10.1016/j.neuroscience.2011.
09.031
Van’t Veer, A., Bechtholt, A. J., Onvani, S., Potter, D., Wang, Y., Liu-
Chen, L. Y., et al. (2013). Ablation of kappa-opioid receptors from brain
dopamine neurons has anxiolytic-like effects and enhances cocaine-induced
plasticity. Neuropsychopharmacology 38, 1585–1597. doi: 10.1038/npp.2
013.58
van Rijn, R. M., and Whistler, J. L. (2009). The delta(1) opioid receptor is a het-
erodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol.
Psychiatry 66, 777–784. doi: 10.1016/j.biopsych.2009.05.019
Vigano, D., Rubino, T., and Parolaro, D. (2005). Molecular and cellular basis of
cannabinoid and opioid interactions. Pharmacol. Biochem. Behav. 81, 360–368.
doi: 10.1016/j.pbb.2005.01.021
Vinod, K. Y., Sanguino, E., Yalamanchili, R., Manzanares, J., and Hungund,
B. L. (2008). Manipulation of fatty acid amide hydrolase functional activity
alters sensitivity and dependence to ethanol. J. Neurochem. 104, 233–243. doi:
10.1111/j.1471-4159.2007.04956.x
Weibel, R., Reiss, D., Karchewski, L., Gardon, O., Matifas, A., Filliol, D., et al. (2013).
Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-
induced analgesia: insight from conditional knockout mice. PLoS ONE 8:e74706.
doi: 10.1371/journal.pone.0074706
Wise, L. E., Shelton, C. C., Cravatt, B. F., Martin, B. R., and Lichtman, A. H. (2007).
Assessment of anandamide’s pharmacological effects in mice deﬁcient of both
fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur. J. Pharmacol.
557, 44–48. doi: 10.1016/j.ejphar.2006.11.002
Wotherspoon, G., Fox, A., Mcintyre, P., Colley, S., Bevan, S., and Winter,
J. (2005). Peripheral nerve injury induces cannabinoid receptor 2 pro-
tein expression in rat sensory neurons. Neuroscience 135, 235–245. doi:
10.1016/j.neuroscience.2005.06.009
Xi, Z. X., Peng, X. Q., Li, X., Song, R., Zhang, H. Y., Liu, Q. R., et al. (2011). Brain
cannabinoid CB(2) receptors modulate cocaine’s actions in mice. Nat. Neurosci.
14, 1160–1166. doi: 10.1038/nn.2874
Yaswen, L., Diehl, N., Brennan, M. B., and Hochgeschwender, U. (1999). Obesity
in the mouse model of pro-opiomelanocortin deﬁciency responds to peripheral
melanocortin. Nat. Med. 5, 1066–1070. doi: 10.1038/12506
Yoshino,H.,Miyamae, T., Hansen, G., Zambrowicz, B., Flynn,M., Pedicord, D., et al.
(2011). Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid
suppression of inhibition in mouse prefrontal cortex. J. Physiol. 589, 4857–4884.
doi: 10.1113/jphysiol.2011.212225
Zanettini, C., Panlilio, L. V., Alicki, M., Goldberg, S. R., Haller, J., and Yasar,
S. (2011). Effects of endocannabinoid system modulation on cognitive and
emotional behavior. Front. Behav. Neurosci. 5:57. doi: 10.3389/fnbeh.2011.00057
Zhang, H. Y., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., et al. (2014).
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity
and dopamine-related behavior in mice. Proc. Natl. Acad. Sci. U.S.A. doi:
10.1073/pnas.1413210111
Zhu, Y., King, M. A., Schuller, A. G., Nitsche, J. F., Reidl, M., Elde, R. P., et al. (1999).
Retention of supraspinal delta-like analgesia and loss of morphine tolerance in
delta opioid receptor knockout mice. Neuron 24, 243–252. doi: 10.1016/S0896-
6273(00)80836-3
Zimmer, A., Valjent, E., Konig, M., Zimmer, A. M., Robledo, P., Hahn, H., et al.
(2001). Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-
deﬁcient mice. J. Neurosci. 21, 9499–9505.
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner,
T. I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid
CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 5780–5785. doi:
10.1073/pnas.96.10.5780
Conflict of Interest Statement:The author declares that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 07 November 2014; paper pending published: 27 November 2014; accepted:
08 January 2015; published online: 05 February 2015.
Citation: Befort K (2015) Interactions of the opioid and cannabinoid systems in reward:
Insights from knockout studies. Front. Pharmacol. 6:6. doi: 10.3389/fphar.2015.00006
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Pharmacology.
Copyright©2015Befort. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
www.frontiersin.org February 2015 | Volume 6 | Article 6 | 15
